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Antigen presentation is the first step in generating an adaptive immune 
response to a foreign pathogen. The antigen processing system digests 
antigens into small peptide fragments, which are bound to major 
histocompatibility complex (MHC) molecules to be presented to T cells. 
Our study focuses on the MHC class II (MHC II) system, which is 
responsible for presenting antigens to CD4+ T cells. Here, we examine 
the function of the MHC II accessory molecule HLA-DO (DO), and its 
interaction with another accessory molecule HLA-DM (DM), to regulate 
the nature of the peptides presented to CD4+ T cells. Although the genes 
encoding the DO proteins are evolutionary conserved in the MHC of 
mammals, their functions have not been well studied. To directly 
examine DO function, we designed a recombinant soluble DO 
heterodimer and tested its effect on peptide binding in vitro. The leading 
model proposes that DO inhibits the effects of DM, but we show that DO 
can interact directly with the MHC II molecule HLA-DR1 (DR1) and have 
both inhibitory and enhancing effects depending on the affinity of DR1 
for the peptide. Based on our observations, DO only regulates peptide 
association but not dissociation. We constructed a molecular model for 
the mechanism of DO in which DO binds to the peptide-receptive MHC II 
molecules that DM generates, either by dissociating the bound peptides, 
or opening the empty groove. This model was verified through Surface 
Plasmon Resonance (SPR) experiments in addition to specific peptide-
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binding studies. We conclude that the role for DO is not to inhibit the 
function of DM, but rather to enforce it, adding another layer of control 
on peptide selection.  
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* Parts of this chapter are adapted from a published review co-authored by 
Yuri  Poluektov, titled “HLA-DO and its role in antigen presentation” 
[Frontiers in Immunology, August 2013] 
 
T cells are of critical importance in the initiation of an adaptive immune 
response. They are the first cells to detect the presence of foreign 
antigens and signal an immune cascade to begin fighting an infection 
that cannot be subdued by the innate system. There are at least two 
classes of T cells: CD8+ T cells are primarily responsible for destroying 
cells containing internal pathogens, and CD4+ T cells that deal with 
external pathogens in addition to enhancing the immune response and 
helping B cell to initiate the production of antibodies against the 
pathogen. T cells are activated upon recognition of a peptide of a given 
antigen bound to the groove of Major Histocompatibility Complex (MHC) 
proteins presenting fragments of antigenic proteins. When a pathogen is 
introduced into the body of the host, be it a virus, bacteria or even a 
multicellular parasite, some of its antigenic proteins are processed by the 
antigen processing system. The processing system digests the full protein 
leaving behind only small peptide fragments. Those fragments are then 
bound to MHC molecules and presented to T cells. If the antigenic 
protein is sufficiently different from peptide fragments generated from 
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self-proteins T cells will respond and initiate an immune reaction. 
Similar to most biological systems, MHC molecules do not act alone and 
are constantly supported by various accessory and processing molecules 
comprising the antigen presentation system. Even a small dysfunction in 
one of the accessory molecules could lead to an improper simulation of T 
cells resulting in the onset of disease. By studying the molecular 
mechanism of the accessory molecules, as well as their modes of 
interaction among them, we hope to be able to manipulate the 
presentation of antigens to T cells; i.e., suppress the presentation of self-
reactive peptides that may result in autoimmune pathologies, or enhance 
the presentation of foreign antigens to fight pathogens. 
 
Class II antigen processing 
Antigens are either handled by the MHC class I or class II antigen 
processing systems. Class I molecules are expressed virtually by all 
nucleated cells while class II is only utilized by professional Antigen 
Presenting Cells (APCs) – Macrophages, B cells and Dendritic cells, as 
well as thymic epithelial cells. MHC class I molecules are primarily 
responsible for presenting peptide fragments of proteins derived from 
endogenous sources while MHC Class II process exogenous proteins from 
the extracellular space. Cross-presentation can occur between the two 
systems and peptides from extracellular antigens can be presented by 
class I molecules and vice versa. However, it is only the class I molecules 
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that present antigenic peptide fragments to “cytotoxic” CD8+ T cells, 
while MHC II molecules present their peptides to “helper” CD4+ T cells. 
Both classes are equally important for the immune system, but our 
research project focuses on the Class II system and its accessory 
molecules in particular.  
 
MHC Class II molecules (MHC II) are transmembrane glycoproteins 
consisting of one α-chain of approximately 34 kD and one β-chain of 
approximately 28 kD combined into a heterodimer1. Classical MHC II 
molecules form a receptive groove in between their alpha and beta chains 
that is able to bind peptides and present them on the cell surface. Non-
classical MHC II are non-polymorphic and serve as chaperones and 
accessory proteins helping in folding, transport, antigenic peptide 
loading, and editing. The most well studied MHC II accessory molecules, 
while also composed of transmembrane heterodimeric glycoproteins, do 
not form a receptive groove that can bind peptides for presentation to T 
cells and are not transported to the cell surface. Instead accessory 
molecules interact with classical MHC II to affect its binding of peptides. 
As is the case with the accessory molecule HLA-DM(DM) that greatly 
facilitates the loading of antigenic peptides into the MHC peptide-binding 
groove. We and others have shown that DM interacts with MHC class II 
and induces conformational changes in the MHC molecule that cause the 
release of the bound peptide and the generation of a peptide-receptive 
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conformation2,3.The effect of DM on the immune system can be visualized 
in knockout mice through their display of altered antigen presentation, 
which in some cases is associated with susceptibility to autoimmunity4–8. 
HLA-DO (DO) is another class II accessory molecule, which unlike DM 
does not have a visible effect on antigen presentation. One of its unique 
qualities is that DO stably interacts with DM and can even be co-
precipitated as a complex. In fact, the transport of DO out of the ER 
depends upon its assembly with DM9, indicating its importance in class 
II antigen presentation. The study of DO presents a unique opportunity 
to discover a new non-invasive method to alter MHC class II antigen 
presentation. A mechanism to regulate the function of DO if developed, 
could be used in therapy without the fear of causing systemic anomalies 
that occur in DM knockout models. At the same time, the function of DO 
could be inhibited or enhanced to reduce specific pathological conditions.  
 
Discovery of DO and its variable tissue expression 
One of the inherent difficulties in studying MHC class II molecules is the 
fact that alpha and beta chains of the molecules do not, in many cases, 
reside in close proximity to each other. This is especially true for DO. 
When first discovered, DO beta chain was thought to be an alternative 
beta chain for MHC class II molecule I-A and designated as Aβ210. It was 
not until years later that the corresponding DO alpha chain was found in 
a study that used an antibody against the predicted cytoplasmic tail of 
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the beta chain to pull down the entire molecular complex and separate it 
by two-dimensional gel electrophoresis11. In addition, the same study 
discovered one of the most unusual features of DO – its variable tissue 
distribution. Unlike MHC II molecules and DM which were expressed in 
all professional APCs, DO was expressed only in B cell dependent areas 
of secondary lymphoid tissues and a few sparse locations in the thymic 
medulla. In addition, it was later discovered that the expression of DO in 
B cells was up- or down-regulated depending on the stage of 
development and activation12,13. Only after migration to the spleen do B 
cells express detectable levels of DO, which are maintained in all 
transitional B cell subsets and mature cells. However, this expression 
level is significantly down-regulated after B Cell Receptor (BCR) 
stimulation and migration into germinal centers. 
 
Studies of human DO analog produced similar results with expression in 
B cells and thymic epithelium9,14,15. Specifically, DO is expressed in 
epithelial cells ringing the Hassall's corpuscles (HC) structures, which do 
not exist in mice as well defined structures. Little is known about the 
true purpose of HCs in the human immune system, although some 
studies have linked them to the generation of regulatory T cells and 
autoimmune disease16, resulting in speculation about the role of DO in 
autoimmunity. The HC bodies are the only sites within human thymic 
medulla where dying thymocytes could be detected outside of the thymic 
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cortex, which implies an important mechanism in negative selection. 
More recently, other differences in mouse and human levels of DO 
expression have been found in certain subsets of dendritic cells (DCs). 
Most notable are the BDCA-3+ subset of human blood plasmacytoid DCs, 
which uniformly express DO, subpopulations of BDCA1+ CD11c+ DCs, 
and tonsillar interdigitating DCs17.  
 
The variable expression of DO compared to MHC II molecules and DM, as 
well as its up- and down-regulation during the B cell cycle, hint at DO’s 
ability to perform a unique function in the MHC class II processing 
system. DO is evolutionary conserved among mammalian species, in one 
case it was even observed that it has been under a strong selection for its 
conservation18–20. It has even been reported that a point mutation in the 
human HLA-DOα gene was linked to a suseptibility to rheumatoid 
arthritis (RA)21, suggesting that the effects of DO on the immune system 
are far reaching. 
 
Functions of DO observed in vivo 
Despite its evolutionary importance, DO has not yet been directly 
implicated as a significant factor in any disease. At first it appeared that 
DO had a distinct negative effect on antigen presentation.Cell lines used 
as surrogate APCs through transfection of DR1, DM and DO genes 
showed a higher abundance of CLIP bound to DR1 then in the absence of 
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DO22. Theseresults suggested that DO was an inhibitor of DM, 
specifically regulating DM’s ability to dissociate CLIP and promote the 
binding of other antigenic peptides. This theory does not, however, take 
into account the fact that B cells from DO knockout mice expressed CLIP 
at similar levels as their wild-type counterparts23,24.In general, results 
from transfected cells were contradictory to those found in vivo and no 
experiment could determine the exact effects that DO had on antigen 
presentation23–25. One of the biggest breakthroughs in studying the 
effects of DO in vivo occurred when investigators began to overexpress 
DO in CD11c+ DCs. Those mice were crossed with non-obese diabetic 
(NOD) mice to generate NOD mice with overexpressed DO in DCs 
(NOD.DO)26. The results were quite overwhelming in that NOD.DO mice 
failed to develop diabetes even after 50 weeks of observation. They did, 
however, develop diabetes upon receiving donor T cells from wild type 
NOD mice. When NOD.DO T cells were transferred into NOD.scid hosts 
lacking T and B cells, mice developed diabetes. Yi et. al. went through 
great lengths to document that the overexpression of DO did not 
suppress the generation of diabetogenic T cells or increased the 
activation of T regulatory cells (Tregs). Instead, DO altered the frequency 
at which diabetogenic T cells were activated through modulating antigen 
presentation. Another study found that DO knock-out mice could 
spontaneously develop high titers of antinuclear antibodies (ANAs), 
indicative of a mouse model of autoimmune systemic lupus 
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erythematosis27. The mice did not, however, develop an autoimmune 
pathology associated with lupus, but showed a reduced capacity to 
present exogenous antigens to helper T cells. 
 
The results observed in transgenic NOD mice and DO knockouts, while 
significant, did not provide insights into the mechanism of DO. This 
allowed the original paradigm of DO as an inhibitor of DM to largely 
remain unopposed. The only experimental evidence to the contrary came 
from a study which looked at the ability of B cells in DO knockout and 
wild-type mice to enter germinal centers (GCs)28. The study reasoned 
that because the expression of DO was down-regulated upon entry to 
GC, DO may be affecting the ability of B cells to enter the GCs. Authors 
proposed that if DO had a measurable effect on the presentation of 
antigens on the cell surface, it would also have had some effect on the 
ability of B cells to receive CD4+ T cell help, and hence enter the GCs. To 
test this hypothesis a 1:1 mixture of DO knockout and wild-type B cells 
specific for the 4-hydroxy-3-nitrophenyl acetyl ligand (NP) were 
adoptively transferred to B6 recipient mice. Mice were then immunized 
with NP-linked chicken gamma globulin (CGG), and then the abundance 
of DO knock-out and wild type B cells in the GCs were measured twenty 
days later. The study found that DO knockout cells outnumbered wild 
type B cells by a ratio of 3 to 1. However, when NP-linked ovalbumin 
(OVA) was used as an antigen, the effect was reversed. This time wild 
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type B cells expressing DO outnumbered the DO knockout cells in the 
GCs. These observations demonstrate that the effect of DO on antigen 
presentation can vary depending on the antigen, and the theory that DO 
is an inhibitor of DM does not explain how DO works.. The function of 
DO is extremely hard to pinpoint with in vivo models due to the 
complexity of the antigen presenting system, hence a need for 
biochemical and structural studies of simplified in vitro MHC II systems 
is apparent. 
 
Mechanistic and structural studies of DO 
Most mechanistic studies to date start with the assumption that DO 
inhibits DM function, and as such are limited in their interpretation. 
While DM inhibition may be one of DO’s functions, as it was observed in 
some of the earliest biochemical assays performed with purified DM/DO 
complexes22,29, it should not be viewed as the only role of DO in antigen 
processing. One study suggested that the ability of DO to inhibit DM was 
pH dependent – evident only in the pH 5.5 – 6.0 range and absent in the 
pH 4.5 – 5.0 range23 – which might be a clue toward DO’s ultimate role. 
Many studies, however, continue to view DO as an inhibitor of DM30,31. 
 
An examples of DO as an inhibitor of DM was generated with the 3-D 
crystal structure of the DM/DO complex32. Through biochemical 
experiments Guce et. al. showed that binding of DO to DM reduced its 
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ability to enhance binding of a variant of HA-306-318 peptide of the 
influenza Texas77 strain to the MHC class II molecule HLA-DR1 (DR1), 
or to dissociate CLIP. More importantly, the interface of DM that was 
primarily utilized in its interaction with DO was the same as the one 
used by DM to exert its effect on DR1, as is evident from the DM/DR1 
crystal structure33,34. Thus the structure of the DO in complex with DM 
superimposed well with the known structure of DR135. The same held 
true for the conformation of DM when compared with the previously 
solved unbound DM structures36,37. These structures suggest that DO 
acts as a structural mimic of MHC II, which upon binding to DM 
prevents it from functioning as an accessory molecule for MHC II. While 
the interface between DM and DO may be the same or similar as that 
between DM and DR1, it is important to emphasize that the stability of 
each complex is different. While the DM/DO complex is highly stable 
under most conditions, the generation of the DM-DR1 complex requires 
conformational changes to occur in the DR1 molecule, including the 
generation of a peptide-receptive-DR1 complex38,39. Even though the 
evidence of the ability of DO to inhibit the function of DM is strong, it 
would be premature to assume that this is the only function of DO. It is 
unlikely that this accessory molecule survived this long in multiple 
species without accumulating any polymorphism if its only function is to 
disable another accessory molecule.  
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Alternative models to explain the function of DO have been proposed in 
the past. Unfortunately, not much work has been done to test these 
models. One notable study reported that DM/DO complexes purified 
from the human spleen had a positive effect on the loading of HA peptide 
onto DR4, DR1 and DR3 molecules as compared to purified DM alone40. 
Interestingly, the study replicated this same result with a recombinant 
form of DO instead of the cell purified molecules. More importantly, the 
study included elution experiments from DR4 molecules using a 
predetermined array of eight peptides. The addition of DO changed the 
repertoire of the eluted peptides as compared to DM. In the presence of 
DM, four of eight peptides were predominantly loaded onto the DR4 
molecules, but when both DM and DO were present, a different set of 
four out of eight peptides was detected. These findings strongly suggest 
that like DM, DO can up- or down-modulate the presentation of certain 
peptides. With that mindset our lab decided to undertake a study of DO 
in a cell-free system to determine the exact conditions necessary for DO 
to inhibit the association as well as dissociation of peptides to DR141. 
 
DO can both inhibit and enhance peptide loading on DR1 
Our kinetic binding assays showed that in addition to inhibiting the 
binding of some peptides to DR1, DO can also enhance the binding of 
others. In Chapter 2, working with soluble recombinant DM, DO and 
DR1 constructs we show that DO enhanced the binding of the HA-306-
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318 as well as H5N1-HA1(259–274) peptides to DR1, while diminishing 
the binding of CII(259–273) and HA-306-318 peptide derivatives with 
weak anchoring residues positioned in the P1 pocket of the MHC II 
molecule. This characteristic of DO is detected both in the presence and 
the absence of DM, and even more surprising, in conjunction with DM’s 
ability to enhance peptide presentation. Interestingly, the peptides 
selected for by DO seem to take priority over DM’s choices, when it 
comes to the inhibitory effects of DO. The regulatory activity of DO 
manifests itself during the association of peptides to DR1 and is 
undetectable during the dissociation phase. The effect of DO is detectable 
in both its free form, as well as in the DM/DO complex generated by 
producing both proteins in the same cells. This indicates that although 
DO will probably inhibit the effect of DM in the DM/DO complex, this 
binding event does not diminish the activity of DO. We suggest a model 
in which DM is used to generate a peptide-receptive conformation3,42,43 in 
MHC II molecules, which DO then uses as a substrate to perform an 
additional round of selection by limiting which peptides can bind to the 
peptide-receptive MHC II. 
 
DO interacts directly with DR1 and not through modulating DM 
In Chapter 3 we confirm our model by testing the ability of DO to interact 
with peptide-receptive DR1 molecules. We present evidence that DO can 
interact with DR1 in the absence of DM by showing both the enhancing 
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and diminishing effect of DO on peptide-receptive DR1 molecules. In 
addition, DO did not lose its ability to diminish the binding of peptides to 
a mutant DR1 molecule stabilized in a peptide-receptive conformation. 
As a validation of this interaction we detected the binding of DO 
molecules to peptide-receptive DR1 through SRP experiments on the 
BIAcore 1000 instrument. DO bound to both peptide-receptive mutant 
DR1 molecules as well as wild-type DR1 in the presence of DM, but failed 
to bind to HA-306-318 peptide loaded DR1. This allowed us to propose a 
hypothetical model for the mechanism of DO interaction with MHC II, 
and we suggest that DO only interacts with MHC II in a peptide-receptive 
conformation, normally generated through the action of DM. Once the 
MHC II is receptive and free of peptides, a DO/MHC II complex is formed 
allowing for more efficient binding of peptides with strong anchoring 
residues. Peptides with weak anchoring residues, especially in the P1 
pocket, do not bind to the DO-DR1 complex as efficiently. Since DM 
equally enhances the binding of all peptides to DR1, the ability of DO to 
select for some peptides over others may in fact seem like an inhibition of 
DM’s function, while the actual role of DO is greater. We propose that DO 
is not an inhibitor of DM but a “second editor of the peptide repertoire” 
presented by MHC II. As such, DM serves as the primary editor of the 
peptide repertoire by dissociating CLIP and other weak-anchored, or 
“DM-sensitive”, peptides from MHC II and leaving it in a receptive 
conformation. DO then acts on the resulting receptive DR1 to add its 
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own layer of selection by allowing only peptides with strong anchoring 
residues, mostly “DM-insensitive,” to bind. Thereby DM and DO work 
together to select for the “best” peptides to be presented by MHC II 
molecules to T cells for stimulation. 
 
DO changes the selection of antigens presented by DR1 
To validate our mechanistic findings we examined the ability of DO to 
regulate the processing of a full length antigenic protein into peptide 
fragments selected by DR1 for presentation. In Chapter 4 we utilize our 
minimalistic cell-free system44 to determine sequences of peptides that 
remain bound to the DR1 molecule upon full antigenic processing in the 
presence and absence of DO. We found that the presence of DO had little 
effect on selecting a known immunodominant antigenic peptide from the 
H5N1-HA1 protein, which was mainly selected by the actions of DM. In 
contrast, we detected a significant decrease in the amount of a known 
DR1 antigenic peptide epitope selected by DR1 molecules in the presence 
of DO or even both DM and DO when compared to DM alone. As a 
validation of our biochemical experiments where DR1 molecules were 
exposed to only a handful of synthetic peptides to determine the effects of 
DO, we find that DO has a translatable effect on the selection of 
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DO can have variable effects on peptide binding to DR1, depending 
on the peptide structure 
* Parts of this chapter are adapted from a published article co-authored by 
Yuri  Poluektov, titled “HLA-DO as the optimizer of epitope selection for 
MHC class II antigen presentation” [PLoS One, August, 2013] 
 
Introduction 
DO is an accessory molecule of the MHC Class II system that has had an 
evolutionary presence in the MHC locus in some of the earliest 
mammalian species1–3. But unlike DM the function of DO has remained 
elusive. Upon synthesis in the endoplasmic reticulum (ER), membrane 
bound classical MHC II molecules assemble into heterodimers composed 
of an alpha and beta chain. To prevent the MHC II molecules from 
binding to proteins and peptides present in the ER, their peptide binding 
groove is blocked by a tight interaction with the membrane bound 
protein known as the Invariant chain (Ii), which also increases the 
stability of the MHC II molecules. When transported to the specialized 
endosomal compartment, known as MIIC, where class II molecules are 
exposed to antigenic proteins, Ii is digested away and only a small 
fragment of it called CLIP remains bound to the MHC II groove4. One of 
the main functions of DM is to dissociate the CLIP peptide from MHC II 
so that antigenic peptides may bind to their grooves5–8. This process is of 
22 
 
utmost importance to class II antigen presentation and its dysfunction is 
visualized in DM knockout experiments9–12. DO knockout experiments, 
on the other hand, never resulted in a clear phenotype. This is 
surprising, given that DO was originally found to form a strong complex 
with DM13. It was even proposed that the function of DO is to inhibit DM, 
but that theory could never be completely confirmed or disproved14. 
 
In order to address the confusion in the field our lab has performed a 
series of biochemical experiments to discern the function of DO. Unlike 
most studies dealing with cells15 and in vivo DO knock-out models16–18 
we took a minimalistic approach to determine the effects of DO on 
peptide loading. The MHC II system is extremely complex to study in vivo 
and there are too many triggers that can be engaged by removing or 
altering an accessory molecule in the system. This creates a complicated 
chain of events that obscures the antigen presentation mechanism, 
making it impossible to distinguish between cause and effect. With this 
in mind, we decided to examine the effects of DO in vitro, as we have in 
the past for other MHC Class II molecules19–22, by examining the effects 
of recombinant soluble DO molecules (missing the transmembrane 
domain) on the binding of peptides to recombinant DR1 in the presence 
or absence of DM. We utilized this technique to determine how DO 
regulates the loading and dissociation of peptides from DR1. Our results 
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suggest that the effect of DO is variable and most likely dependent on the 
ability of DM to dissociate the peptide. 
 
Materials and methods 
 
A. Production of soluble recombinant MHC class II proteins 
Soluble DR1, DM and DO proteins were expressed and purified as 
originally described23,24. Baculovirus DNA (BacculoGold; BD Biosciences, 
San Jose, CA) and transfer vectors carrying the recombinant soluble 
forms of the alpha and beta chains of DR1, DM and DO were transfected 
into SF9 insect cells for recombinant virus production, as suggested by 
the BacculoGold protocol. Hi5 cells, upon reaching a concentration of ≈ 
1x106 cells/ml were infected with the recombinant virus and grown in 
suspension in shaker flasks for 3 days following infection for protein 
production. Soluble DR1 was purified from both the cells and culture 
supernatant using anti-DR1 mAb (L243) coupled resin. For the 
purification of HLA-DM and HLA-DO, the protocol was modified to use 
the M2 FLAG (Sigma-Aldrich, St. Louis, MO, USA) and Ni-NTA (QIAGEN, 
Valencia, CA, USA) affinity columns respectively using gravity flow. Upon 
elution from the columns DM and DO molecules were concentrated (20-
40 μM) in Citrate Phosphate pH 6.0 buffer with 0.05% NaN3 and stored 
frozen at -80°C in small aliquots. The soluble DR1 heterodimers were 




B. Peptide synthesis and labeling 
Peptides used in our binding experiments were synthesized to a 
minimum of 90% purity (Global Peptide Services, currently Pi 
Proteomics, Huntsville, AL, USA), as confirmed by HPLC and mass spec 
documentation from the company. All peptides in our study were derived 
from characterized immunodominant HLA-DR1 (human MHC class II) 
binding peptides. The peptides were labeled with Fluorescein on their N-
terminus with either fluorescein-5-maelimide (Molecular Probes), when 
the peptide had an added Cysteine residue on the N-terminus, or with 
fluorescein 5,6 succinimidyl ester (Molecular Probes) directly to the N-
terminus, as per manufacturers suggested protocol. The labeled peptides 
were concentrated to 0.05 ml by SpeedVac (Savant Instruments, Inc.) 
and excess free fluorescein was removed by passing the sample through 
a Sephadex G-10 column (Sigma-Aldrich). The concentration of the 
peptide was determined according to the extinction coefficient of 
Fluorescein (83 mM-1 cm-1).  
Sequence of peptides used in the study:     
 
HA(306-318): CPKYVKQNTLKLAT 
(derived from Texas 77 flu strain HA protein peptide) 
HA(Y308A): PKAVKQNTLKLAT 
(Texas 77 flu strain HA protein peptide variant)  
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HA(anchorless):  CPKAVKANGAKAAT 
(Texas 77 flu strain HA protein peptide variant)  
CII(259-273):  CAGFKGEQGPKGEP  
(derived from Type II Collagen peptide used to induce arthritis in mice 
models)  
H5N1-HA1(259-274): SNGNFIAPEYAYKIVK  
(derived from A/Vietnam/1203/2004 flu strain peptide25) 
 
C. Peptide association and dissociation kinetics  
Peptide binding experiments were performed as described previously20–
22,26.In brief, we performed all binding experiments at 37ºC in Citrate-
Phosphate buffer, pH 5.0. Wt DR1 (1 μM) was incubated with fluorescent 
peptides (30 μM) in association experiments. For dissociation 
experiments we used DR1/fluorescent peptide complexes formed over 3 
days incubation in 37°C, a competing non-fluoresceinated HA(306-318) 
peptide was added to the dissociation reaction at a concentration of 50 
μM. In kinetics experiments where DO and DM were included, 
concentrations of 1 μM for DM and 4 μM DO or DM/DO were used. For 
each of the experimental combinations of DR1 with DM and DO, the 
binding of peptide to DR1 was measured at eight different time points: 
10h, 5h, 3h, 2h, 1h, 0.5h, 0.25h, 0h, unless otherwise indicated. Excess 
unbound peptide was removed using Sephadex G-50 size-exclusion spin 
columns. As a test for complete peptide removal as well as non-specific 
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binding, all association assays included binding controls of peptide alone 
or with accessory molecules incubated for over 10 hours at 37°C. 
Binding control values were included in the corresponding figure legends. 
Fluorescence signal of peptide/DR1 complexes was measured by a 
Horiba FluoroMax®-3 instrument (Horiba Ltd., Kyoto, Japan) at 514-
520 nm with an excitation wavelength of 492 nm and a 2 nm slit width. 
 
D. Surface Plasmon Resonance measurements of protein binding  
SPR experiments were performed as described previously26 on a BIAcore 
1000 instrument (GE Healthcare). Anti-His tag (Invitrogen), Anti-FLAG 
tag (Sigma-Aldrich), and Anti-HA tag (Sigma-Aldrich) antibodies were 
immobilized on CM5 chips (GE Healthcare) through standard amine 
coupling procedures. Excess activated dextran carboxylate groups were 
capped with 2-amino-ethyl-sulfate (pH 8.0) to decrease the nonspecific 
binding of MHC molecules to the chip surface at a lower pH27. All protein 
solutions were diluted in the running buffer composed of Citrate-
Phosphate pH 5.5 with 150 mM NaCl, 0.005% Tween-20 and 0.05% 
NaN3. Measurements were taken at 27°C with flow rates ranging between 
5-10 μl/min.MHC II proteins were injected at concentrations of 4μM 





All kinetic experiments performed were analyzed with OriginPro 7.0 
software. Association data was fitted by a single exponential association 
equation (BoxLucas1 fit curve): 
Y = A1(1-e-x/t) 
Dissociation data was fitted by a single exponential dissociation equation 
(ExpDec1 fit curve): 
Y = A1e-x/t 
Where x is the number of hours the DR1 molecule was incubated with 
peptide in the presence of accessory molecules and Y is the resulting 
fluorescence signal that is read in the Fluorimeter. For association 
kinetics the units of the Y-values were expressed as x103 Arbitrary 
Fluorescence Units (AFU). The dissociation Y-values were normalized to 
the RFU signal of the 0 hour time point and expressed as % of peptide 
remaining, taking the starting point to be 100%. We opted out of trying 
to fit our data with double exponential curves, as it was not sensitive 





A. Soluble recombinant DO molecules expressed are properly folded 
and resemble the structural features of a native DO heterodimer 
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Although previously we were successful with our soluble recombinant 
MHC II molecules, it is always necessary to confirm that a new 
recombinant molecule is properly folded and structurally identical to its 
native counterpart. The native from of DO, like all other MHC II, contains 
a transmembrane domain which links the heterodimer to the membrane. 
The MHC II transmembrane domain rarely has been implicated in having 
an effect on the function of the molecules28, and can be removed without 
any detectable consequences. Unfortunately, DO alpha and beta chains 
do not dimerize as readily as DM or DR1 and even require the presence 
of DM for proper dimerization and transportation into specialized 
endosomal MHC class II compartments (MIICs)13,29. To solve this, we 
removed the transmembrane domain of DO in our recombinant molecule 
and instead replaced it with a Leucine zipper domain (acidic – α chain, 
basic – β chain) (Fig. 1). We also added a thrombin cleavage site in the 
alpha and beta chains as well as a Histidine tag on the α and an HA tag 
on the β chain for identification and purification purposes. Spacers were 
inserted in between the new structures to give the alpha and beta chains 
enough flexibility to form stable heterodimers. Recombinant soluble DO 
was expressed in Hi5 insect cells and purified via the Ni-NTA (anti-His 
tag) column. The molecule purified in this way was not ‘clean’ and its 
alpha (MW ≈ 31 kDa before glycosylation) and beta (MW ≈ 32 kDa before 
glycosylation) chains were barely detectable on a silver stain gel (Fig. 
2A). Since DO was originally found to have a strong association to the 
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DM molecule13 we decided to see if our recombinant molecule could form 
a stable complex with recombinant DM. To ensure the formation of the 
complex we decided to co-infect the viral constructs of both recombinant 
DM and DO molecules into the same Hi5 cells. The resulting protein was 
purified not through an affinity tag, but by the means of a conformation-
specific antibody generated upon immunizing mice with DM/DO 
complexes naturally expressed in B cells30.This antibody (Mags.DO5) was 
covalently coupled to Sepharose beads and used to purify DM/DO 
complexes through gravity flow. DM/DO was eluted with CAPS buffer pH 
11.5 and buffer exchanged into Citrate-Phosphate buffer pH 6.0. The 
presence of the alpha and beta chain of both DM and DO in the complex 
was verified via replicate western blots specific for each of the chains 
(Fig.2B)(DO-α-His-tag; DO-β-HA-tag; DM-α-FLAG-tag; DM-β-C-Myc-tag). 
As a verification of the Western BLOTs, the presence of the His- and HA- 
tags on DO in the DM/DO complex was verified through SPR 
experiments on the BIAcore 1000. Mags.DO5 purified DM/DO complexes 
bound both the anti-His and anti-HA antibodies immobilized on CM5 
chips through amine coupling (Fig.3A-B), while soluble recombinant DM 
and DR1 did not. Finally, as a validation of the proper tertiary structure 
of our soluble DO, we purified DM/DO complexes with a Ni-NTA column 
specific against the DOα chain Histidine tag and tested its binding to the 
conformation specific Mags.DO5 antibody. DM/DO purified with the His- 
tag bound to immobilized Mags.DO5 at a level of about 600 relative units 
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(RU). At the same time, Mags.DO5 failed to bind DM alone of His- 
purified DM/DO that was pre-incubated with soluble Mags.DO5 prior to 
injection into the BIAcore instrument (Fig.4). This indicates that our 
insect-expressed recombinant DO folds with sufficient similarity to its B 
cell-expressed counterpart to reproduce the natural epitope. We have 
exhausted all possible methods of validating the structure of our 
recombinant DO short of determining a three dimensional crystal 
structure of the molecule31. 
 
B. Storage of DO in a neutral pH buffer leads to its inactivation 
Our first kinetic experiments with our recombinant DO were not 
successful; DO seemed to have little to no effect on the binding of 
peptides to DR1 within a 10 hour period. The effects of DM could be 
visualized within 15-30 minutes of incubation of DR1 with peptide20. The 
first batches of purified DO molecules were stored in PBS, just like DR1, 
but this storage buffer modified the properties of our recombinant DO, 
causing it to aggregate. Preserving DO in a buffer of pH 7.0 showed a 
lower number of DO dimers as determined by a sizing HPLC column 
(Fig.5). At pH 7.0, the amount of 50-60 KDa DO dimer is much lower 
than if DO is stored at pH 6.0. This was critical for the effect of DO when 
looking at its ability to diminish peptide binding to DR1 molecules. We 
tested the effects of DO, both in the presence and absence of DM, on the 
binding of a type II collagen derived peptide CII(259-273) to DR1. DO 
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stored at pH 7.4 had no effect on the association of CII(259-273) to DR1 
while DO stored at pH 6.0 clearly diminished the binding of peptide 
(Fig.6).  
 
C. DO can have both enhancing and diminishing effects on peptide 
binding to DR1 
After determining the storage conditions for our DO molecules we tested 
its effect on the kinetics of association and dissociation of peptides to 
and from DR1. While DO diminished the binding of CII(259-273) peptide 
to DR1, it had little to no effect on the dissociation of the same peptide 
from DR1, both in the presence and absence of DM (Fig.7). A similar 
result was produced when testing our DO with a variant HA peptide 
molecule lacking all of its anchoring positions – HA(anchorless). 
HA(anchorless) is a variant of HA (306-318) of influenza 
immunodominant epitope that dissociates rapidly from DR1. The 
dissociation process is even further enhanced by the action of DM32. Just 
like with CII(259-273), DO did not change the dissociation rate of 
HA(anchorless) (Fig.8). But the association of HA(anchorless) to DR1 was 
almost completely inhibited by DO unlike with CII(259-273) peptide, 
where DO only diminished the binding but did not prevent it altogether. 
More importantly, the association of HA(anchorless) was inhibited by DO 




Our experiments with CII(259-273) and HA(anchorless) peptides 
demonstrated that DO can have a negative effect on peptide binding, 
similar to reports from other labs15,33. In this case both peptides had 
weak anchoring residues and were easily dissociated by DM. What came 
as a surprise was the observation that DO could also have positive effects 
on the binding of peptides to DR1. When tested with peptides that were 
not sensitive to dissociation by DM (DM-insensitive), DO showed an 
enhancing effect in the binding of both HA(306-318) (Fig.9) and H5N1-
HA1(259-274) (Fig.10) peptides. In each case DO had no effect on the 
dissociation of the peptide, but the association seemed to be significantly 
enhanced. In addition, the effects of DO seemed to be cooperative with 
those of DM. Furthermore, even DO alone increased the ability of DR1 to 
bind peptides nearly to the same level as DM. Since HA(306-318) has a 
long halftime of dissociation, we performed an extended DR1 dissociation 
experiment to determine if the effects of DO become visible at time points 
beyond the 10 hour mark (Fig.11). Even after 100 hours of dissociation 
the amount of peptide bound to DR1 while being in the presence of both 
DM and DO was not any different than in the presence of DM alone. The 
soluble DR1 molecules were degrading faster than the accessory 
molecules could affect the dissociation of peptides bound to them.  
 
D. DO forms a complex with DM and upon formation the DM/DO 
complex has the same effect on peptide binding as DO alone 
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The ability of DO to bind DM was one of the first observations made in 
the study of DO13. We have verified that DO can form a complex with DM 
if both molecules are synthesized in the same cell (Fig.4), but can soluble 
DO also form a complex with DM?  To examine this notion, we 
immobilized DO on the surface of a CM5 chip with covalently coupled 
anti-His Ab. Once the dissociation of DO from the antibody reached a 
stable phase that did not alter the signal by more than 10RU/min, we 
injected soluble DM over the immobilized DO. This resulted in DM 
binding to DO with a signal difference of 490 RU between the start and 
the end of the injection of DM (Fig.12A). A reverse approach with 
immobilizing DM to an anti-FLAG tag antibody coupled chip surface and 
injecting DO led to binding of DO that increased with its increasing 
concentrations (Fig.12B). Measuring the difference in RU between the 
start and the end of the injection of DO allowed us to plot the amount of 
DO bound to DM (in RU – Y-axis) versus the concentration of DO injected 
(in µM – X-axis) (Fig.12C). By fitting the points with a Langmuir 1:1 
binding isotherm equation: Y = Max * X/(X + Kd), we are able to 
determine the Kd of DO binding to DM. Our numbers approximated the 
Kd to be ≈0.5 μM. 
 
While, even in its soluble form, DO is able to bind DM, we questioned 
how this might affect the ability of DO to influence peptide binding to 
DR1. To this end we examined the effect of DM/DO complexes purified 
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through the DOα Histidine tag on the binding of HA(Y308A) peptide to 
DR1 (Fig.13). HA(Y308A) has a alanine substitution at its critical P1 
pocket anchoring residue making it sensitive to dissociation by DM. To 
our surprise, DM/DO complexes acted exactly like DO alone on 
inhibiting the binding of the peptide. Even when the DM/DO was 
supplemented with additional DM, it did not modify the effect of DO. This 




Most studies to date have had trouble determining the effects of 
DO16,17,34. The generally accepted model assumes that DO is an inhibitor 
of DM14. Our studies showed that the function of DO is much more 
complicated than originally thought. The ability of DO to inhibit the 
binding of certain peptides is unquestionable, but we show that DO also 
has opposite effects on binding of other peptides. Our peptide association 
experiments have demonstrated that CII(259-273), HA(anchorless) and 
HA(Y308A) peptides are diminished or completely inhibited in their 
binding to DR1 in the presence of DO. As is evident from our dissociation 
experiments, HA(anchorless) nearly completely dissociates from DR1 
within 2-3 hours of incubation with DM or both DM and DO accessory 
molecules present (Fig.8). CII(259-273), on the other hand, is less 
susceptible to the effects of DM and it could take up to 10 hours to get it 
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to dissociate completely in the presence of DM (Fig.7). The inhibiting 
effects of DO on CII(259-273) binding to DR1 are much less pronounced 
than on HA(anchorless), leading us to hypothesize that the effect of DO is 
linked to the sensitivity of the peptide to dissociation by DM, since the 
faster the dissociation rate of the peptide, the more inhibition of its 
binding is caused by DO. If, however, the peptide is virtually insensitive 
to dissociation by DM, like HA(306-318) and H5N1-HA1(259-274), then 
the inhibition of DO is reversed and the binding of the peptide to DR1 is 
enhanced (Fig.9-10). This provides evidence for DO not simply being an 
inhibitor, but an accessory molecule able to edit the repertoire of 
peptides bound to DR1, while selecting for some peptides and excluding 
others. The difference between HA(306-318) and HA(Y308A) peptides is 
only one residue, that stabilizes the peptide in the P1 pocket of the DR1 
molecule. By changing this residue we are not only able to adjust the 
sensitivity of the peptide to DM dissociation, but also the effect DO would 
have on its binding to DR1 (Fig.13). The ability of DO to shift the peptide 
binding repertoire by both enhancing and diminishing the binding of 
peptides has been observed before35. Kropshofer et al. also attributed the 
effect of DO on peptide selection to the activity of DM, but the study did 
not specify a mechanism for this dependence.  
 
It is important to note, that while the binding of CII(259-273) peptide in 
the presence of DO is diminished (Fig.7), the addition of DM in 
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combination with DO to the reaction is able to restore some of the 
binding but not to the same level as that of DM alone. When we examine 
the association of HA(anchorless) to DR1, this is not the case. The 
inhibition of DO cannot be reversed by the addition of DM (Fig.8). This 
would indicate that the mechanism of action of DO and DM is separate 
and that the effect of DO is dominant over that of DM. On the other 
hand, when we observe the ability of DO to enhance the binding of DM-
insensitive peptides, we see an almost cooperative effect between the two 
accessory molecules (Fig.9-10). The enhancing effect of DO and DM 
together produced more DR1/peptide complexes than either DO or DM 
alone. Although evidence seems to point strongly toward the mechanisms 
of DM and DO being distinct, we would need additional experiments 
presented in Chapter 3, to make a definitive statement. 
 
We have demonstrated that while being able to form complexes with DM, 
DO did not lose its activity. A DM/DO complex molecule has the same 
effect on the binding of peptides to DR1 as DO alone (Fig.13). Guce et al. 
has provided strong evidence in the analysis of the crystal structure of 
the DM/DO complex that that the interface of the interaction between 
DM and DO blocks the residues necessary for DM to interact with 
DR131,36. This does not, however, suggest that DO in complex with DM 
would also lose its activity, since we do not know the nature of the 
residues important for the DO function. In addition, the interaction 
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between DM and DO, although structurally similar to the interaction 
between DR1 and DM37, cannot be considered the same since the 
stability of the DM/DO complex greatly exceeds that of DM/DR1. DO, 
while being a structural mimic of DR1, acts as a unique accessory 
molecule in the MHC class II system imposing its exclusive layer of 






















Figure 1. Soluble recombinant HLA-DO. 

























Figure 2. Recombinant soluble DO characterization. 
(A) Gentle SDS (0.2% SDS) gel of purified soluble DO and DR1 on a 12% 
Tris-HCl gel. 
(B) Soluble co-expressed DO/DM complex was purified using Mags.DO5 
monoclonal antibody affinity column. Four replicate samples were 
resolved on Bis-Tris SDS-PAGE gels in decreasing protein 
concentrations. Gels were blotted to PVDF membranes and stained for 






































Figure 3. Recombinant DO Characterization on BIAcore 1000. 
(A)  SPR sensograms of DR (red trace), DM (blue trace) and co-expressed 
DM/DO complexes (Mags.DO5 purified) (green trace) binding to anti-HA 
antibody coupled chip surfaces.  
(B) SPR sensograms of DR (red trace), DM (blue trace) and DM/DO 









































Figure 4. Recombinant DM/DO complex is recognizable by 
Mags.DO5 conformation specific antibody. 
SPR sensograms showing binding of DM/DO (Ni-NTA purified) (green 
trace), DM (red trace), and DM/DO (Ni-NTA purified) pre-bound to 
























Figure 5. DO storage conditions affect its function. 
HPLC traces of recombinant DO stored in buffers of varying pH. DO was 
run through a SuperdexTM 200 10/300 GL size exclusion column at 
0.2ml/min for 70 minutes. The HPLC mass standards are displayed in 
































Figure 6. Only DO stored at pH 6.0 can have an effect on CII(259-
273) peptide binding to DR1. 
Association of CII(259-273) peptide to DR1 molecules with no accessory 
molecules (black squares), with DM (red dots), with DO (green triangles), 
or both DO and DM (blue triangles) over the course of 10 hours. DO used 
in experiment on the left was stored at pH 7.4 (PBS) while the DO used 










Figure 7. DO diminishes binding of CII(259-273)  peptide to DR1 
molecules. 
Association (top) and dissociation (bottom) of CII(259-273) peptide to 
DR1 molecules with no accessory molecules (black squares), with DM 
(red dots), with DO (green triangles), or both DO and DM (blue triangles) 
over the course of 10 hours. The fluorescence signals (Arbitrary 
Fluorescence Units) associated with the control samples incubated > 10 
hours in the absence of DR1 were measured: CII(259-273)  peptide alone, 
3996; CII(259-273) + DM, 1026; CII(259-273) + DO, 3326; CII(259-273)  































Figure 8. DO diminishes binding of HA(anchorless)peptide to DR1 
molecules. 
Association (top) and dissociation (bottom) of HA(anchorless) peptide to 
DR1 molecules with no accessory molecules (black squares), with DM 
(red dots), DO (green triangles) or both DO and DM (blue triangles) over 
the course of 10 hours. The fluorescence signals (Arbitrary Fluorescence 
Units) associated with the control samples incubated > 10 hours in the 
absence of DR1 were measured: HA(anchorless) peptide alone, 3364; 
HA(anchorless) + DM, 1334; HA(anchorless) + DO, 1558; HA(anchorless) 








































Figure 9. DO can increase the binding of HA(306-318) peptide to 
DR1 molecules.  
 Association (top) and dissociation (bottom) of HA(306-318) peptide to 
DR1 molecules with no accessory molecules (black squares), with DM 
(red dots), DO (green triangles) or both DO and DM (blue triangles) over 
the course of 10 hours. The fluorescence signals (Arbitrary Fluorescence 
Units) associated with the control samples incubated > 10 hours in the 
absence of DR1 were measured: HA(306-318) peptide alone, 1390; 







































Figure 10. DO can increase the binding of H5N1-HA1(259-
274)peptide to DR1 molecules.  
Association (top) and dissociation (bottom) of H5N1-HA1(259-274) flu 
peptide to DR1 molecules with no accessory molecules (black squares), 
with DM (red dots), DO (green triangles) or both DO and DM (blue 
triangles) over the course of 10 hours. The fluorescence signals (Arbitrary 
Fluorescence Units) associated with the control samples incubated > 10 
hours in the absence of DR1 were measured:  H5N1-HA1(259-274) 
peptide alone, 1312; H5N1-HA1(259-274) + DM, 1250; H5N1-HA1(259-






































Figure 11. DO does not affect the dissociation of HA(306-318) even 
after 96 hours of incubation.  
Prolonged 96 hour dissociation experiment of HA(306-318) peptide from 
DR1 molecules with DM (red dots) or both DO and DM (blue triangles). 
































Figure 12. Soluble recombinant DO forms a complex with soluble 
recombinant DM. 
(A) DO (Ni-NTA purified) was immobilized on an anti-His antibody surface 
(blue trace). After a brief wash, DM was injected over the captured DO 
(green trace).A control injection of DM over anti-His antibody surface (red 
trace) showed no non-specific binding. Data shown are representative of 
six independent experiments.  
(B) DO (Ni-NTA purified) binding to DM immobilized by anti-FLAG 
antibody surface in concentrations ranging from 0.01 to 10 μM in 
separate experiments. 
(C) Langmuir 1:1 binding isotherm fit of DO bound to DM (RU) versus the 
concentration of DO. The equation: Y = Max * X/(X + Kd), was used to 
determine the Kd of DO binding to DM. Our fit approximated the Kd to 
































Figure 13. DO in complex with DM is functionally active. 
Association of HA(Y308A) peptide to DR1 molecules in the presence of co-
infected DM/DO complex (Ni-NTA purified). The peptide binding 
experiment was performed with no accessory molecules (black squares), 
with DM (red dots), DM/DO (green triangles), or both DM/DO and DM 
(blue triangles) over the course of 10 hours. The fluorescence signals 
(Arbitrary Fluorescence Units) associated with the control samples 
incubated > 10 hours in the absence of DR1 were measured: HA(Y308A) 
peptide alone, 1140; HA(Y308A) + DM, 894; HA(Y308A) + DM/DO, 1404; 
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DO acts independently of DM by forming a complex with DR1 when 
DR1 is in a peptide-receptive conformation 
* Parts of this chapter are adapted from a published article co-authored by 
Yuri  Poluektov, titled “HLA-DO as the optimizer of epitope selection for 
MHC class II antigen presentation” [PLoS One, August, 2013] 
 
Introduction 
Studies on DO have failed to produce a unified opinion on its role in the 
MHC II antigen processing system. Initial findings have made a strong 
case for DM and DO having a linked function, due to DO’s reliance on 
DM for intracellular transport and assembly1. Many studies have 
attributed the effects of DO to the dampening of peptide binding to MHC 
II molecules through its interaction with DM2–4. In contrast, other reports 
have shown the contrary by identifying DO as an enhancer of peptide 
presentation5–7. For the most part, studies of DO examined complex in 
vivo systems that made conclusions based on the final outcome of 
antigen presentation. This makes it hard to develop a mechanism 
through which DO might interact with DM to diminish or even enhance 
peptide presentation. In our study, described in Chapter 2, we took a 
minimalistic approach and examined the direct effect of DO on antigen 
presentation. We utilized well known techniques established by our and 
other labs in the field to examine the direct effect of soluble recombinant 
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DO on peptide association and dissociation from soluble recombinant 
DR1.This same approach was used in the past to establish the role of 
CLIP as a place-keeper for the MHC class II groove, inhibiting 
conformational changes that lead to the inactivation of MHC II before it is 
able to bind antigenic peptides8–15. In addition, this approach laid the 
foundation for the theory behind the ability of DM to edit the MHC II 
peptide repertoire by recognizing the heterogeneous conformations of 
DR116–20. Now we investigate the structural features of the antigenic 
peptides that have impacts on how DO may regulate their presentation. 
 
The experiments described in Chapter 2 established that DO can have 
both enhancing and diminishing effects on peptide binding to DR1. To 
verify the specificity of this effect, we performed a DO depletion 
experiment where anti-His tag Ab as well as MAGS.DO5 Ab resin were 
used to deplete DO from the reaction, and observed a decrease in both 
the enhancing and diminishing effects of DO. The variation in the DO 
effect seems to correlate with the strength of the anchoring residues of 
the peptide; specifically, the amino acid that fits into the P1 pocket of the 
DR1 molecule. It has been shown that the interaction of an antigenic 
peptide with the P1 pocket of the DR1 molecule is most important in its 
ability to generate an immunodominant response as well as determining 
whether DM is able to dissociate it19. It is of little surprise that this 
critical peptide residue would have an effect on DO as well as DM. This 
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may explain the observed dependence between DM and DO5,21. The 
association of DM sensitive peptides, HA(Y308A) and HA(anchorless), to 
DR1 in the presence of DO has indicated that the effect of DO is superior 
to that of DM and that there is a strong possibility that DO acts 
independently of DM. To validate this, we performed additional kinetic 
experiments with peptide-receptive DR1 molecules. We hypothesize that 
not only is DO capable of interacting with DR1 independently of DM, but 
that it interacts exclusively with DR1 molecules in its receptive 
conformation.  
 
The result of a peptide-association experiment with the mutant 
DR1βG86Y molecule, which is permanently stabilized in a peptide-
receptive conformation and does not interact with DM19,22,23, showed that 
DO still maintains its ability to inhibit peptide dissociation even when 
DM is no longer active. This provides strong evidence for DO having a 
unique function independent of DM. Via SPR, we observed direct binding 
between DO and peptide-receptive, but not closed or compact, 
peptide/DR1 complexes. We find that the binding is maintained even 
when DM/DO complexes are used instead of DO alone, further validating 
our observation that DO in complex with DM retains its unique function.  
 
Considering all of our data, we have constructed a model for the 
mechanism of peptide epitope selection on MHC II by DO. We 
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hypothesize that DO requires DM to generate a peptide-receptive 
conformation in MHC II molecules, after which DO can bind the receptive 
molecule and stabilize it in a form that allows for effective binding of 
long-lived peptides (generally DM-insensitive) and diminishes the binding 
of short-lived peptides that dissociate from MHC II within hours (DM-
sensitive). Thereby DO acts not to inhibit DM but to supplement DM's 
ability to select for highly stable antigenic peptides to serve as 
immunodominant epitopes to be presented to T cells. While DM works by 
dissociating unstable peptides from MHC II, DO prevents the binding of 
those same peptides once the MHC II molecule is in a peptide-receptive 
conformation. 
 
Materials and methods 
 
A. Production of soluble recombinant MHC class II proteins 
Soluble DR1, DM, DO and mutant DR1βG86Y proteins were expressed 
and purified as originally described in Chapter 2. Baculovirus DNA 
(BacculoGold; BD Biosciences, San Jose, CA) and transfer vectors 
carrying the recombinant soluble forms of the alpha and beta chains of 
DR1, DM and DO were transfected into SF9 insect cells for recombinant 
virus production, as suggested by the BacculoGold protocol. Hi5 cells, 
upon reaching a concentration of ≈ 1x106 cells/ml were infected with the 
recombinant virus and grown in suspension in shaker flasks for 3 days 
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following infection for protein production. Soluble DR1 and mutant 
DR1βG86Y was purified from both the cells and culture supernatant 
using anti-DR1 mAb (L243) coupled resin. For the purification of DM and 
DO, the protocol was modified to use the M2 FLAG (Sigma-Aldrich, St. 
Louis, MO, USA) and Ni-NTA (QIAGEN, Valencia, CA, USA) affinity 
columns respectively using gravity flow. Upon elution from the columns 
DM and DO molecules were concentrated (20-40 μM) in Citrate 
Phosphate pH 6.0 buffer with 0.05% NaN3 and stored frozen at -80°C in 
small aliquots. The soluble DR1 heterodimers were kept in PBS pH 7.4 
with 0.05% NaN3. 
 
B. Peptide synthesis and labeling 
See Chapter 2. 
 
C. Peptide association and dissociation assays 
See Chapter 2. 
 
D. Generation of the peptide-receptive DR1 complex 
Peptide-receptive DR1 was induced by incubating empty DR1 (1-10 μM) 
molecules with excess amount of unlabeled HA(anchorless) peptide (100 
μM) for three days. Before the start of an experiment which required the 
use of receptive DR1, generated in the absence of DM, 
DR1/HA(anchorless) complexes were separated from the excess peptide 
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by Sephadex G-50 size-exclusion spin columns. Due to the rapid 
dissociation of HA(anchorless) peptide from DR1, a (T1/2 ~90 min), a 
significant number of DR1 molecules convert to a DR-receptive state 
within a short time14. Any long-lived peptide would displace 
HA(anchorless) and bind to DR1 molecules as if they were receptive. 
 
E. DO depletion through immunoprecipitation 
DO was depleted from our DO containing samples by tandem 
incubations with Ni-NTA and Mags.DO5 antibody resins. First DO (4 μM) 
was added to 20-25 μl of 50 % slurry of Ni-NTA resin and incubated for 
20 minutes. The resin was then spun in a table top centrifuge and the 
supernatant was collected and added to 20-25 μl of 50 % slurry of 
Mags.DO5 resin. After another 20 minutes of incubation the Mags.DO5 
resin was spun and the supernatant containing the depleted DO was 
added directly to the binding reaction.  
 
F. Surface Plasmon Resonance measurements of protein binding  
SPR experiments were performed as described previously on a BIAcore 
1000 instrument (GE Healthcare)24.Anti-His tag (Invitrogen) antibody was 
coupled to CM5 chips (GE Healthcare) through standard amine coupling 
procedures. Excess activated dextran carboxylate groups were capped 
with 2-amino-ethyl-sulfate (pH 8.0) to decrease the nonspecific binding of 
MHC molecules to the chip surface at a lower pH25. DO or DM/DO 
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complexes (4 μM) were immobilized on top of the anti-His tag antibody. 
DR1 receptive or closed and mutant DR1βG86Y (4 μM) were then tested 
for binding to DO. All protein solutions were diluted in the running buffer 
composed of Citrate-Phosphate pH 5.5 with 150 mM NaCl, 0.005% 
Tween-20 and 0.05% NaN3. Measurements were taken at 27°C with flow 
rates ranging between 5-10 μl/min. The magnitude of binding was 








A. The effect of DO on peptide binding to DR1 is the direct result of 
DO  
As a validation of our peptide association and dissociation experiments 
that showed DO could have both an enhancing and a diminishing effect 
on peptide binding to DR1, we tested the specificity of this effect. For this 
purpose DO was depleted from the sample by tandem runs 
immunoprecipitation (IP) over anti-His antibody and a conformation-
specific antibody (Mags.DO5) resin (see Materials and Methods). The 
sample of DO depleted as such was compared to the samples with and 
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without DO for their ability to diminish the binding of HA(anchorless) 
peptide (Fig.1A) or enhance the binding of HA(306-318) peptide (Fig.1B) 
after a 5 hour incubation with DR1. In both cases the depletion of DO 
resulted in a decrease in the diminution of the binding of HA(anchorless) 
(Fig.1A 2nd and 5th bars)and the enhancing effect on the binding of 
HA(306-318) (Fig.1B 2nd and 5th bars). Both experiments were repeated 
in the presence of DM, and in each case the depletion of DO through IP 
decreased its effect on the binding of peptides. This strongly suggests 
that both the decrease and increase in binding of peptides can be 
attributed to the DO molecule and not any other protein. 
 
 
B. DO acts directly on DR1 rather than by modifying DM 
Peptide association experiments described in Chapter 2 demonstrated 
that for HA(anchorless) and HA(Y308A) peptides DO plays an 
overwhelming role even in the presence of DM. If DO were to inhibit DM, 
the decrease in peptide binding to DR1 in the presence of DO would have 
been different when both DM and DO were present. In both cases 
however, the decrease in binding induced by DO was the same, strongly 
suggesting that DO acts directly on DR. To test this idea we examined 




Because DO did not affect dissociation of peptide/DR complexes, a 
process that DM does best, we hypothesized that perhaps DO can only 
interact with a receptive DR1. To test this idea, peptide-receptive DR1 
was generated by incubating DR1 molecules with HA(anchorless) peptide 
and separating the peptide/DR1 complexes from excess peptide and then 
allowing DR1 to incubate at 37 °C for a few minutes (see materials and 
methods). Because of short half-life of  HA(anchorless)/DR1 complexes a 
peptide-receptive conformation would be generated when the peptide 
dissociates from DR119. As such, we are able to monitor the effect of DO 
on the binding of HA(306-318) (Fig.2A) and CII(259-273) (Fig.2B) to 
receptive DR1 molecules. While no DM was present in the system, DO 
was still able to enhance the binding of HA(306-318) and slightly 
diminish the binding of CII(259-273) to DR1, as was observed in Chapter 
2. The absence of DM did not prevent DO from affecting peptide 
association to DR1, as long as the peptide-receptive conformation was 
induced. 
 
C. DO is able to interact with a mutant DR1 molecule constitutively 
in a peptide-receptive conformation 
To further evaluate the idea that DO interacts with a peptide-receptive 
conformation of DR1, we examined the effect of DO on a mutant 
DR1βG86Y molecule. This mutant DR1 has a filled P1 pocket which 
forces it to remain in a peptide-receptive conformation, unable to shift to 
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a closed compact form19,22,23. In addition, this mutation prevents the DR1 
molecule from binding most long-lived peptides with bulky residues 
destined for the P1 pocket. If the effect of DO is similar to that of DM 
then it should not be detectable with mutant DR1βG86Y, since DM 
enhances the binding of peptides by forcing the MHC II molecules to 
adopt a peptide-receptive conformation.  
We monitored association kinetics of HA(anchorless) peptide to mutant 
DR1βG86Y over the course of 10 hours (Fig. 3A). To our surprise, despite 
the inability of DM to enhance peptide binding to DR1βG86Y, DO could 
still perform its function of diminishing the binding of HA(anchorless), as 
previously observed in Chapter 2. This suggests that DO does not 
participate in the generation of peptide-receptive DR1 molecules.  
 
D. DO forms a stable complex with mutant DR1βG86Y molecules but 
not compact closed DR1 
All of our observations point towards DO interacting with receptive DR1 
molecules. If this is indeed the case, there is a possibility we might be 
able to detect a complex formation between DO and receptive DR1 using 
the SPR technique. The ability of SPR to detect the binding of MHC II 
molecules has been previously demonstrated in a study that observed 
the interactions of DM and DR120. If the DO/DR1 complex is stable 
enough we would be able to visualize the binding between the two 
molecules in our BIAcore 1000 instrument. For this purpose we captured 
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DO on anti-His antibody immobilized CM5 chip followed by the injection 
of mutant DR1βG86Y molecules (Fig. 4). Approximately100 RU was 
detected upon completion of DO injection indicating that complexes were 
formed between DO and DR1βG86Y (Fig. 4 inset). In a control 
experiment when closed compact DR1/HA(306-318) was injected over 
immobilized DO, the detected binding was 20 RU (Fig. 5). A 20 RU 
binding corresponds to our background level of interaction between DR1 
and the anti-His antibody immobilized surface (Fig. 4-5). 
 
Our data from Chapter 2 suggests that DM/DO complexes act like DO 
alone. To explore this observation further, we tested the ability of 
DM/DO complexes to bind to DR1βG86Y. DM/DO molecules were 
captured by immobilized anti-His antibody surface to a total signal of 
2000-3000 RUs. Then, DR1βG86Y molecules were injected in three 
concentrations of 0.5, 1 and 2 μM over the DM/DO captured surface 
(Fig. 6A). Repeat injections of increasing concentrations of DR1βG86Y 
were performed on the same flow cell following the prolonged dissociation 
of the bound DR molecules (0.5 μM) or a regeneration of the surface with 
the injection of pH 11.5 CAPS buffer, washing the surface overnight in 
running buffer and recapture of 2000-3000 RUs of DM/DO molecules 
before the next injection (1 μM). With increasing concentration of 
DR1βG86Y more binding was measured when the sensogram stabilized 
following the end of the injection. Binding controls were included to rule 
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out any nonspecific binding. Neither DR1βG86Y at 4 μM when injected 
over anti-His antibody coupled surface, nor 4 μM of pre-formed HA(306-
318)/DR1complexes (closed conformer) injected over the DM/DO bound 
surface produced noticeable binding. In order to make sure that the 
observed binding was specific to DO and not DM in complex with DO, 
DR1βG86Y and DR1-HA molecules were injected over DM molecules 
captured by an anti-FLAG antibody coupled chip surface (Fig. 6B). The 
binding of HA(306-318)/DR1 molecules to DM remained at a minimal 
level of 20 RU, whereas DR1βG86Y binding to DM resulted in 35 RU. In 
each case the signals were significantly smaller than those resulting from 
DR1βG86Y binding to DM/DO complexes at lower concentrations. 
 
While the mutant DR1βG86Y molecule is always receptive, wild-type DR1 
utilizes the help of DM to adopt a receptive conformation. In a full-
fledged MHC II system DM most likely creates the peptide-receptive 
conformation necessary for the function of DO. To test this, a transient 
receptive conformation was generated in DR1 molecules by pre-loading 
them with DM-sensitive HA(Y308A) peptide for 3 days at 37°C 
(HA(Y308A)/DR). Before injection into the BIAcore instrument, excess 
HA(Y308A) peptide was removed through G50 column filtration. DM 
(2μM) was then added to the HA(Y308A)/DR complexes as they were 
incubated at 37°C for 20 minutes. Due to the short half-time of 
dissociation of HA-Y308A and the addition of DM, most of the peptide 
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would dissociate from DR1 molecules leaving them in an open peptide-
receptive conformation. Immediately after the 20 minute incubation this 
solution, which contained peptide-receptive DR1 molecules, DM, and the 
unbound HA(Y308A) peptide was injected over DM/DO captured surface. 
By slowly injecting DR1 molecules at a rate of 1 μl/min for 50 minutes 
we saw a 337 RU binding of DR1-receptive to DM/DO. Since the 
receptive conformation is transient and may not be adopted by all the 
DR1 molecules, unlike with DR1βG86Y, the injection had to be continued 
over a prolonged period of time while keeping the temperature of the 
flow-cell at 37°C to allow further generation of receptive DR1 during the 
injection (Fig. 7). Control injections of 4 μM HA(306-318)/DR1 closed 
conformer under the same conditions produced only 46 RU binding. 
Because DR-receptive molecules included DM, we also injected DM (2 
μM) as control, which resulted in 228 RU of binding. We believe this 
rather high level of DM binding to DM/DO surface is due to dissociation 
of DM from the anti-His captured DM/DO complexes over long 
incubation at 37°C. 
 
Discussion 
Crystallization of the DM/DO complex has led to a model in which upon 
binding to DO, DM is no longer able to function properly26.This, however, 
does not prevent DO from functioning as an accessory molecule as we 
have seen in Chapter 2, figure 13. Moreover, the interaction between DM 
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and DO does not inhibit the complex formation between DM/DO and 
receptive DR1 molecules depicted in figures 6-7. As we have seen from 
our data, as well as past experiments, DO forms a stable complex with 
DM1. Although the true proportion of free versus DO-bound DM has not 
been established, it is generally believed that free DM is present even in 
DO expressing cells27. Our data suggests that both DO and DM/DO 
complexes will only interact with receptive DR1 molecules. Since one of 
the main functions of DM is to stabilize this receptive conformation, we 
hypothesize that the initial action by DM is necessary for DO to perform 
its function properly. This means that great care has to be given when 
constructing an experimental system to determine the effects of DO, 
especially when it comes to transfected cells. If the concentration of DO 
becomes too high, the effects of DO would be hard to detect, since the 
system would be missing DM necessary to generate peptide-receptive 
MHC II molecules that DO can act upon. This may have been one of the 
reasons behind the difficulty in studying DO over the years. 
 
Once DO or DM/DO interacts with receptive DR1 molecules it forces 
another conformational change to occur. It is unlikely that DO simply 
stabilizes the peptide-receptive conformation, since a receptive 
conformation binds all peptides equally regardless of how long- or short-
lived they are. DO, on the other hand, promotes the binding of long-lived 
DM-insensitive peptides while diminishing or even completely inhibiting 
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the binding of short-lived DM-sensitive peptides. In order to explain this 
selection process we like to visualize this new conformation as one that 
has the DR1 peptide binding groove open beyond the receptive state 
(super-receptive). In this new conformation the access to the P1 pocket of 
the DR1 molecule is more readily available, perhaps even the P1 pocket 
itself is wider then in a receptive state. This allows long-lived peptides, 
which generally have a big bulky hydrophobic residue dedicated for the 
P1 pocket, to interact with the P1 pocket more readily then in a receptive 
DR1. This would hold true for short-lived peptides as well. But short-
lived peptides while binding more readily to the P1 pocket would also be 
more prone to dissociation. In the end this would mean that long-lived 
peptides remain bound after the action of DO, while short-lived peptides 
would never get a chance to stabilize themselves in the P1 pocket. 
Putting our results together we are able to purpose a model for the 
mechanism of DO (Fig. 8). We propose that the function of DO is 
dependent on DM generating a peptide-receptive MHC II molecule. Once 
a peptide-receptive MHC is available, DO binds to it to induce a 
conformation different from that of a receptive MHC II. This facilitates the 
binding of long-lived peptides while diminishing the binding of short-lived 
peptides. Instead of acting as an inhibitor or an enhancer of DM, DO has 
its own mode of selection of antigenic peptide epitopes. DO acts as a 
secondary editor of the MHC II peptide repertoire which narrows down 




We have unfortunately not been able to conduct a successful experiment 
to prove the existence of a conformation of DR1 different from receptive 
and closed or compact. We purposed that a DR1 molecule interacting 
with DO would be less stable than empty DR1 alone, due to the super-
receptive conformation it adopts. To test this proposal we tried to 
determine the melting point of DR1 alone and in the presence of DO 
through circular dichroism (CD) studies. Our CD experiments were not 
sensitive enough and produced melting points that were only a few 
degrees apart, with the DR1 sample in the presence of DO being more 
stable than that of DR1 alone (Appendix i). 
 
In a fully functional class II antigen presentation system, we believe that 
DO imposes its own level of control on the structure of the peptides 
selected to be presented to T cells by MHC II molecules. Our proposed 
mechanism for DO implies that the first step of narrowing down the 
peptide repertoire occurs by DM dissociating any unwanted peptides 
from MHC II molecules and leaving them receptive to bind other 
peptides. DO would then select the peptides that should and should not 
bind to the MHC II peptide groove. This effectively means that DO would 
have the final say as to what peptides are presented by MHC II molecules 
and not DM. Although it is not certain to what extent DO would select 
from the available peptide pool generated by DM. This raises many 
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Figure 1. The effect of DO can be diminished by DO depletion 
through immune precipitation. 
(A) DO was depleted from a DO stock by immunoprecipitation via Ni-NTA 
followed by Mags.DO5 resin. The depleted sample was used instead of 
DO in reactions measuring HA(anchorless) peptide/DR complex 
formation in the presence or absence of DM after 5 hours of incubation. 
The fluorescence intensity of peptide/DR1 complexes formed in the DO 
depleted reaction was compared to a reaction containing no DO (left bar 
in each set of three), and a reaction that contained DO that did not 
undergo depletion (right bar in each set of three). The experiment is 
representative of three separate trials.  
(B) A DO-depleted sample was used instead of DO in a reaction 
measuring of HA(306-318) peptide/DR complex formation in the 
presence or absence of DM after 5 hours of incubation. The fluorescence 
intensity of peptide/DR1 complexes formed in the DO depleted reaction 
was compared to a reaction containing no DO (left bar in each set of 
three), and a reaction that contained DO that did not undergo depletion 
























Figure 2. DO affects peptide binding to DR1 independent of DM. 
 (A) Association kinetics of HA(306-318) to peptide-receptive DR1 without 
DO (black triangles) or with DO (red triangles).  
(B) Association kinetics of CII(259-273) to peptide-receptive DR1 without 










































Figure 3. DO acts upon constitutively receptive DR1βG86Y 
molecules. 
(A)  HA(anchorless) association to constitutively receptive mutant 
DR1βG86Y molecules with no accessory molecules (black squares), with 
DM (red dots), DO (green triangles) or both DO and DM (blue triangles). 
The fluorescence signals (Arbitrary Fluorescence Units) associated with 
the control samples incubated > 10 hours in the absence of DR1 were 
measured: HA(anchorless) peptide alone, 1804; HA(anchorless) + DM, 








































Figure 4. DO forms a complex with DR1 in a receptive conformation. 
SPR sensograms of constitutively receptive DR1βG86Y (4μM) binding to 
DO. Ni-NTA purified DO was immobilized on anti-His antibody coupled 
chip (blue trace). After a brief wash, DR1βG86Y was injected over the 
captured DO surface (green trace, enlarged in inset). An injection of 
unloaded DR1 over the anti-His antibody surface (red trace) was 





















Figure 5. DO does not form a complex with DR1 in a compact closed 
conformation. 
SPR sensograms of closed compact DR1/HA(306-318) complex (4μM) 
binding to DO. Ni-NTA purified DO was immobilized on anti-His antibody 
coupled chip (blue trace). After a brief wash, DR1/HA(306-318) was 
injected over the captured DO surface (green trace, enlarged in inset). An 
injection of unloaded DR1 over the anti-His antibody surface (red trace) 























Figure 6. DM/DO forms a complex with peptide-receptive DR1 
molecules. 
(A) DR1βG86Y binding to DM/DO complex molecules. Mags.DO5 purified 
DM/DO was immobilized on anti-His antibody coupled chip surface to a 
level of 2000-3000 RU. After a brief wash, DR1βG86Y was injected over 
the captured DM/DO at concentrations of 0.5 μM (blue trace), 1 μM (red 
trace), 2 μM (green trace). Before every injection of DR1βG86Y, the 
DM/DO molecules captured on the surface were regenerated to insure 
that the surface was not saturated by bound DR1 molecules. The signal 
of the resulting binding ~200-300 after the end of the injection is marked 
on the graph.  
(B) Binding controls of DR1βG86Y and DR1/HA(306-318) with anti-His 
antibody, DM/DO and DM surfaces. Following the immobilization of anti-
His antibody, 4 μM DR1βG86Y (red trace) and 4 μM DR1/HA(306-318) 
(black trace) were injected over the immobilized antibody. Upon 
capturing 2000-3000 RU of DM/DO by the anti-His antibody, 4 μM 
DR1/HA(306-318) was injected over the DM/DO (green trace). In a 
separate control, 3000 RU of DM was captured by immobilized anti-FLAG 
antibody. 4 μM DR1βG86Y (cyan trace), or 4 μM DR1/HA(306-318) (blue 























Figure 7. Transiently receptive DR1 molecules interact with DM/DO 
complexes. 
Mags.DO5 purified DM/DO was immobilized on anti-His antibody 
coupled chip surface to a level of 2000-3000 RU. 4 μM receptive DR1 
with 2 μM DM was injected over the captured DM/DO at a rate of 1 
μl/min and a constant flow-cell temperature of 37°C for 50 minutes 
(green trace). As a control, prior to the injection of receptive DR1 
molecules, 2 μM DM (blue trace), or 4 μMDR1/HA(306-318) (red trace) 




















Figure 8. A model for the mechanism of DO or DM/DO interaction 
with DR1. 
Starting from a CLIP-bound DM-sensitive conformation (conformation 
1), DR interacts with DM (conformation 1’), and a peptide-receptive 
open conformation is generated (conformation 2). An open conformation 
can also be induced by DM interacting with empty DR (conformation 
6’). DO or DM/DO complexes interact with peptide-receptive DR 
molecules and stabilize an overly receptive conformation (conformation 
3). In the pool of available peptides those that form DM-sensitive 
complexes with DR do not get a chance to stabilize in the groove. On the 
contrary, those peptides that form DM-resistant complexes undergo 
conformational changes and form DR-compact dimers (conformation 4), 
which are shuttled to the cell membrane (conformation 5). If DR-
Receptive (conformation 2) does not find a peptide to bind it converts to a 
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DO can skew the selection of the immunodominant peptide epitope 
from the antigenic protein 
 
Introduction 
Our studies on the effect of DO utilized individual peptides and led to a 
model for its role in class II antigen presentation1. However, our model 
needs to be evaluated against antigenic proteins. When an antigenic 
protein enters the class II processing system, it is first exposed to the 
acidic environment with proteases, known as Cathepsins, of the MIIC 
specialized endosomal compartment. Contrary to most text book 
illustrations, the digestion of the protein does not occur before its 
binding to the MHC II molecules. Our lab has observed in numerous 
occasions that the digestion by Cathepsins is rapid and will result in 
complete digestion of the antigenic protein with no peptides left to bind 
the MHC II molecules (Kim et.al, in review). Kim et al demonstrated that 
immunodominant peptide sequences of the antigen need to be protected 
by the MHC groove from being digested. Multiple factors contribute to the 
selection of the immunodominant epitopes that includes; accessibility of 
the epitopes to MHC II molecules, the binding “affinity” of the exposed 
epitopes, the specificity of Cathepsins, the activity of the class II 
accessory molecules, and numerous other factors. It is this very process 
that determines what peptides will be used to stimulate T cells. In order 
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to understand the role of DO in our immune system we have to 
understand how it might affect the selection of immunodominant 
epitopes from full length proteins. 
 
Our laboratory has recently developed a cell-free antigen processing 
system for MHC class II 2. This reductionist system is composed of five 
recombinant soluble proteins involved in MHC II antigen processing, 
namely, recombinant DR1, DM and three Cathepsins (Cat), Cat S, Cat B 
and Cat H. Full-length denatured or native antigenic protein are 
incubated with DR and DM and then cathepsin are added.  DR1, now 
bound to different peptides is immunoprecipitated and subjected to acid 
elution of the peptide.  Mass Spectrometry is used for the identification of 
the peptides.  
 
Once the protein binds to DR1, Cathepsins are introduced into the 
system and any epitope that is not protected by the MHC II groove is 
digested, leaving behind only the long-lived, generally DM-insensitive, 
peptides. DR1 is then immunoprecipitated through the L243 Ab resin 
and the peptides it binds are eluted with trifluoroacetic acid (TFA). Once 





Using our cell free system, we were able to confirm the sequence of 
immunodominant peptides determined through other studies3,4 as well 
as discover new immunodominant epitopes de novo2. In our lab, 
immunodominance is defined by the ability of the peptide to induce the 
same immunologic recall response in T cells as the full length antigenic 
protein following the initial immunization. For the most part, we can find 
the immunodominant epitope of a full length protein by sequencing the 
peptides eluted in our cell free system. In addition to the 
immunodominant peptides there are a number of other non-dominant 
peptides that are eluted from MHC II molecules that do not stimulate T 
cells from full length protein immunized mice. By utilizing this 
minimalistic MHC II processing system we are able to examine the effects 
of DO both with and without DM on the selection of immunodominant 
epitopes for DR1. Our experiments have produced evidence that the 
effect of DO is variable for different antigenic proteins. While having little 
effect on the peptide selection of the H5N1-HA1 protein, DO seems to 
have a strong effect on the selection of the immunodominant type II 
collagen (CII) derived peptide. 
 
Materials and methods 
 
A. Production of soluble recombinant MHC class II proteins 
See Chapter 2. 
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B. MHC II cell-free processing system and Mass-Spec sample 
preparation 
Antigenic full length proteins were pre-bound to DR1 with or without 
accessory molecules in citrate-phosphate pH 5.0 buffers for 3 hours at 
37°C. For each experiment 4 samples and a background without any 
antigenic protein added were prepared:    
1: DR1  
- protein of interest  
- HLA-DR1 
2: DR1+DM 


















Following the 3 hour incubation, reactions were adjusted for processing 
by Cathepsins to digest away the protein leaving behind only the DR1-
bound epitopes. The solution of DR1/protein with Cathepsins B, H and S 
(or alternatively V instead of S)(Calbiochem) was incubated for 2 hours at 
37°C to allow complete digestion, then the reaction was neutralized by 
the addition of 0.2M Na2HPO4. DR1 with bound peptides was 
immunoprecipitated by L243 conformation specific antibody to wash 
away the Cathepsins and the accessory molecules. Peptides were eluted 
form DR1 through the addition of 1% TFA. The eluted peptides were 
separated from DR1 through the use of a 10 kDa Microcon YM – 10 
centrifugal filter unit (Millipore). To prepare the samples for Mass spec, 
the peptides were dried and reconstituted in 50% methanol with the 
addition of 100 fmol of Angiotensin I (DRVYIHPFHL) peptide for the 




A. DO has a minor effect on shifting the repertoire of DR1 molecules 




We set out to determine what the effect of DO and DM accessory 
molecules is on the selection of immunodominant peptides from a full 
length antigen. If the effect of accessory molecules on antigen 
presentation is large enough to affect the onset of disease, then they 
should significantly alter the sequences of peptides that are presented by 
MHC II molecules to T cells. Given the ability of DO to regulate the 
binding of peptides to DR1 and the reports made by some researchers on 
the effect of DO in model systems, we believe that DO should be able to 
make changes in T cell repertoire. To support this theory we wanted to 
find a particular immunodominant epitope the presentation of which 
would be enhanced, diminished or even completely eliminated by the 
presence of DO. 
 
Before performing the digestion of a full length antigenic protein, we 
tested the ability of DO to alter the selection of a peptide by DR1 from a 
set of known immunodominant and non-dominant peptides. 4 samples of 
DR1 with or without accessory molecules were incubated in the presence 
of 250 fmol of HA(306-318), HA(Y308A), CII(259-273), H5N1-HA1(259-
274), DR3 restricted Uveitis peptide, HSA(291-306) 
(NRERRGIALDGKIKHE),and DR3 restricted Thyroglobulin peptide, 
TG(2098-2112) (LSSVVVDPSIRHFDV) (Table 1). After a 3h incubation at 
37°C, DR1 molecules with bound peptides were immunoprecipitated by 
L243 antibody coupled resin. The peptides were eluted from DR1 and 
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reconstituted in 50% methanol. Angiotensin I (DRVYIHPFHL) was added 
to each of the 4 samples to generate the standard peak of relative peptide 
abundance. Samples were analyzed by Matrix-assisted laser 
desorption/ionization-linear trapping quadrupole (MALDI-LTQ) (Thermo 
Fisher) mass spectroscopy. MALDI-LTQ is not a quantitative technique 
and it is hard to know the exact amounts of peptide that each sample 
contains. To assess a relative estimate of the quantities of peptides for 
comparison among different samples, we normalized all of our peptide 
peak signals to the signal generated by the Angiotensin I peptide 
standard (Fig 1). Short-lived peptides which easily dissociate from DR1 
and peptides not restricted to DR1 did not show up in the MALDI 
readings regardless of the presence of DM, or DO. As expected, long-lived 
peptides insensitive to DM-mediated dissociation outcompeted short-
lived ones. While the abundance of CII(259-273) peptide remained 
relatively constant, the abundance of H5N1-HA1(259-274) and HA(306-
318) peptides were increased in the presence of DM, as compared to the 
sample with no accessory molecules. In support of our previous 
observations, the samples containing both DM and DO accessory 
molecules increased the relative abundance of H5N1-HA1(259-274) and 
HA(306-318) peptides even further as compared to the sample containing 
DM alone. This is likely the result of a cooperative effect between DO and 




In these experiments DO did not completely prevent the binding of one 
immunodominant peptide for another in any of the samples. This means 
that the effect of DO is more subtle than we had hoped for. To observe 
the effect of DO we would have to perform the selection of peptides from 
the digestion of a full length protein in our cell free system. This would 
generate a great number of both long- and short lived peptides for DO to 
exert its effect on, as well as give us a chance to gauge the subtle 
changes imposed by DO on the antigenic peptide repertoire. 
 
B. DO has little effect on the selection of the immunodominant 
H5N1-HA1(259-274) peptide from the full length H5N1-HA1 protein 
while still altering the antigenic peptide repertoire 
We were not able to observe the effect of DO on selecting a particular 
immunodominant peptide that could not be selected by either DR1 alone 
or DR1 in the presence of DM.  To better visualize the effect of DO it was 
necessary to process a full length antigen both in presence and the 
absence of DO and to quantitate the relative abundance of both the 
immunodominant as well as the non-dominant epitopes that remained 
bound to DR1.  This way we would be able to show that DO had a 




Our first cell free processing experiment was conducted with a full length 
influenza H5N1-HA1 protein. We have previously determined the 
sequence of its immunodominant epitope, which makes it easier to 
examine if DO has any significant effect on its presentation. Four 
different samples of DR1 were incubated with H5N1-HA1 protein at 37°C 
for 3 hours in the presence of DO and DM in combination with each 
other. Another sample with DR1, DM and DO but no antigenic protein 
was also incubated at 37°C for 3 hours to serve as a Mass-Spec 
background control where all peptide peaks not specific for H5N1-HA1 
protein would be displayed. Cathepsins B, H and S were then added to 
each sample to digest away the protein and the unbound peptides. 
Following a 2 h digestion, DR1 molecules were immunoprecipitated with 
L243 antibody-coupled resin and the bound peptides were acid eluted 
from DR1 with TFA. The eluted peptides were run on a MALDI-LTQ mass 
spectrometer to observe the presence of the immunodominant peaks 
(Fig. 2). Unique peptide peaks in samples were determined by comparing 
the mass spectra to that of the background sample that did not include 
the HA protein. A comparison of the abundance of H5N1-HA1(259-274) 
peptide peaks in samples including DO and DM or DM only suggested 
that addition of DO did not significantly affect the abundance ofHA1(259-
274) peptide in the presence of DM. At the same time, unique peaks at 
1899 and 2675 Da were detected in samples of DR1 alone and DR1 with 
DM respectively. This suggests that DO may have diminished the 
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presentation of a number of non-dominant peptides present in samples 
without DO. 
 
In addition to sequencing our H5N1-HA1 protein derived peptides eluted 
from DR1 we performed a relative quantitation of the abundance of each 
peptide sequence in the sample.  For this purpose a "peptide correlation 
profiling/ion intensities" analysis was performed on each sample. This 
method takes into account both the time of the peptide elution in the MS 
sample as well as the intensity of its signal5,6. Using this technique we 
received a list of peptides derived from the H5N1-HA1 protein identified 
in all 4 samples (Fig. 3A-D). Just as we have seen in our MALDI-LTQ 
profile, no matter what accessory molecules were present, the 
immunodominant H5N1-HA1(259-274) peptide and its variants with 
extended N- and C- terminal residues were always detected. However, the 
amount of the immunodominant peptide in samples with no accessory 
molecules or just the DO accessory molecule was hundreds of times 
smaller. This led us to hypothesize that the presentation of the 
immunodominant H5N1-HA1(259-274) peptide is determined by the 
presence of DM and DO does not play a role in inhibiting DM. The 
peptide fragments presented by each set of accessory molecules were 
derived from the entire sequence of the protein antigens, and few 
fragments were uniquely presented in samples with combinations of 
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accessory molecules (Fig. 3E). As such, H5N1-HA1(259-274) digested in 
the presence of DO, or DO and DM displayed the presence of non-
dominant epitopes, peptides shown as (59 - DLDGVKPLILR – 69) and 
(324 - SNRLVLATGLRNSPQ – 338), while other samples did not.  While in 
the case of the H5N1-HA1 protein DO did not significantly affect the 
presentation of the immunodominant epitope, it was able to alter the 
total antigenic peptide repertoire.   
 
C. DO inhibits the presentation of the immunodominant CII(259-
273) peptide fragment processed from a pre-cut type II collagen 
protein 
The experiment with the processing of the H5N1-HA1 protein showed 
that the presence of an accessory molecule could significantly alter the 
relative abundance of immunodominant peptides compared to their non-
dominant counterparts. In case of H5N1-HA1, it was DM that had the 
largest effect on the presentation of the immunodominant peptide. To 
determine if this remains true for other antigenic proteins we decided to 
examine the effects of DO on the presentation of the type II collagen (CII) 
immunodominant epitope. This immunodominant epitope has been 
previously identified by studies conducted on DR1-transgenic mice3 and 
reconfirmed by our cell-free system2. Due to a high sequence similarity, 
including the immunodominant epitope, we used bovine collagen instead 
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of its human form. Unlike H5N1-HA1, which can be added in its native 
form to the cell-free system, CII has to be first denatured and digested by 
MMP9. CII was boiled in acetic acid and pre-digested by MMP8 activated 
MMP9 before its addition to the cell-free system for processing2. After the 
CII pre-digested fragments bound the DR1 molecules, they were included 
in cell free processing system and the eluted peptides were analyzed by 
MALDI-LTQ. It is important to note that CII(259-273) peptide is not as 
easily digested by Cathepsins as is the H5N1-HA1(259-274) peptide (Kim 
et.al, in review). The peptide peaks varied from one sample to the next 
indicating the ability of DO to alter the antigenic peptide repertoire 
presented by DR1.Unfortunately, we did not detect the immunodominant 
CII(259-273) epitope in any of the samples (Fig. 4). The 
immunodominant epitope and its different length variants were, however, 
identified when the samples were analyzed and sequenced (Fig. 5A-D). 
This time the abundance of the CII(259-273) epitope as well as its 
variants differed in the presence or absence of DO. The immunodominant 
epitope had the highest abundance in the sample containing DM. The 
sample containing DO had nearly 25 times less of the epitope, and the 
sample containing both DM and DO had nearly a 50 fold decrease in the 
amount of immunodominant epitope presented. Just like with H5N1-
HA1, the epitopes presented in the 4 samples of DR1 with and without 
DM and DO were spread out along the sequence of the protein with some 
epitopes being unique to only a few combinations of accessory molecules 
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(Fig. 5E). This is our first confirmation of the ability of DO to 
significantly shift the abundance of the immunodominant peptides 
selected by DR1 for presentation to T cells. 
 
D. Substitution of cathepsin V for cathepsin S prevents the CII(259-
273) epitope from being presented by DR1   
The thymic epithelial cells are some of the few MHC class II presenting 
cells that have been found to express DO6,7. Unlike most MHC II 
molecules DO has only been found to be expressed in B cells, the thymic 
epithelial cells and a few subsets of dendritic cells8. Specifically, DO is 
expressed in epithelial cells ringing the Hassall's corpuscles (HC) 
structures. Not much is known about the true purpose of those 
structures, although they have been previously implicated in the 
generation of T regulatory cells9,10. We hypothesized that the presence of 
DO in the thymic epithelia, while being absent from DCs and 
Macrophages, serves some specific function. To mimic the effect of DO in 
the thymic epithelial cells we altered the Cathepsins used in our cell free 
system. In all of our experiments so far, we used Cathepsins B, H and S 
for the digestion of antigens. Cathepsin S while being important in the 
MHC II processing system11,12, is not expressed in the thymic medullary 
cells that show expression of DO13. Instead thymic epithelial cells 
express Cathepsin V (also known as L2) or its mouse analog Cathepsin 
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L14–16. As an experiment we decided to substitute Cathepsin S in our 
system with Cathepsin V and see if in combination with DO the 
repertoire of peptides would be different.  
 
We repeated our cell-free system experiment with CII protein this time 
substituting Cathepsin S with Cathepsin V. Surprisingly, the sequencing 
results showed a complete lack of the immunodominant CII(259-273) 
epitope or its variants (Fig. 6A-D), at the same time, another epitope, not 
present in the previous experiment was detected in a few samples. The 
location of the epitopes selected in the presence of Cathepsin V from the 
sequence of the full length protein was with only a few exceptions very 
similar to our previous result (Fig. 6E). This experiment shows that not 
only the accessory molecules, but also the proteases in antigen 




Our cell-free experiments have provided significant insights into the MHC 
class II antigen presentation system. In our previous studies2,17, the DR1 
molecules that were used in the cell-free system were preloaded with a 
short-lived, DM-sensitive peptide – HA(Y308A). DR1 molecules become 
instantly receptive when HA(Y308A) dissociates, which promotes a better 
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binding of the antigenic protein during the pre-binding step, before the 
Cathepsins are introduced. This approach generally resulted in similar 
levels of immunodominant peptide presented both in the presence and 
absence of DM. It is important to note that HA(Y308A)18, has a similar 
half-time of dissociation in the presence of DM as does the CLIP 
peptide19. But we do not know how substituting HA(Y308A) for CLIP may 
affect the final outcome of presented peptide epitopes. In experiments 
described in Chapter 4 the DR1 used in the cell free system was not pre-
loaded with HA(Y308A). We believe that this allowed us to better observe 
the differences in peptide loading in the presence of accessory molecules. 
The relative amount of immunodominant H5N1-HA1 as well as CII 
derived peptides that were eluted from DR1 in the absence of DM and DO 
is significantly less than the amounts eluted in the presence of DM, DO 
and even DM and DO together, highlighting the importance of MHC II 
accessory molecules (Fig. 3,5). While we are still not certain how this 
observation might be translated to the peptide selection process 
occurring in vivo, our results confirm that the binding of peptides to DR1 
depends on DM and DO. 
 
The processing of H5N1-HA1 protein, as observed in our cell-free system, 
has identified DM as the molecule being primarily responsible for the 
presentation of its immunodominant epitope. The presence of DM has 
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increased the relative amount of immunodominant peptide and its 
various size variants by a factor of 100 as compared to the samples 
where H5N1-HA1 protein was processed by DR1 alone or DR1 with DO 
(Fig. 3). To our surprise, although DO enhanced the presentation of 
H5N1-HA1(259-274) peptide (see Chapter 2), it did not increase the 
relative amount of the immunodominant peptide variants by itself or in 
the presence of DM. It is important to note that when the same samples 
were analyzed by spectral counting, we saw an increase in the number of 
immunodominant H5N1-HA1(259-274) peptide PSMs associated with the 
sample containing both DM and DO (86 PSMs) as opposed to DM alone 
(52 PSMs). This necessitates further experimentation to determine the 
effects of DO on the selection of peptides from a full length antigen. This 
will allow us to expand on our mechanistic model for the effects of DO, 
taking into account the data we have already generated for individual 
peptides. 
 
DO played a primary role in the inhibition of the selection of CII 
immunodominant epitopes. While the amount of immunodominant 
epitopes in the presence of DM was not very significant, in samples 
containing DO and both DM and DO accessory molecules it decreased by 
more than 20 fold (Fig. 5). While we do not know if this decrease is 
sufficient  to prevent rheumatoid arthritis (RA), we have just found our 
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first evidence of DO having an observable effect in a disease model. This 
is not the first time DO has been linked to RA. In a population study 
conducted amongst RA patients a specific SNP in an un-translated region 
of the HLA-DOα gene was linked to the onset of the disease20. We believe 
that it is important to follow up on this discovery and conduct additional 
in vivo experiments in DO knock-out mouse models to confirm this 
association. 
 
Our experiment with an alternate Cathepsin has shown us that not only 
class II accessory molecules, but the proteases in the MIIC compartment 
may have a significant effect on the nature of the peptide repertoire 
presented by MHC II molecules. While we have known about the variable 
expression of different types of Cathepsins in human tissues11,13,16, we 
have only had associative evidence for their importance in antigen 
presentation12,15. With the establishment of the cell-free system, we can 
now observe the direct effect that specific Cathepsins may have in the 
processing of antigens leading to the onset of disease. Our discovery of 
CII protein being processed differently in the presence of thymic 
Cathepsin V as compared to Cathepsin S (Fig. 6), expressed in DCs, B 
cells and Macrophages, allows us to speculate on the mechanism of 
autoimmune disease initiation. While the thymic medullary 
compartments process CII in addition to many other potential 
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autoimmune proteins with Cathepsin V, the immunodominant epitopes 
responsible for the onset of disease are simply not presented. This leads 
to a lack of negative selection of self-reactive T cells in the thymus. At the 
same time, CII can be pre-digested and processed in the periphery by 
antigen presenting cells that express Cathepsin S, which from our 
experiments is necessary to present the immunodominant epitope. This 
would allow T cells that escaped negative selection to be triggered by 
immunodominant CII peptides present in the periphery resulting in 
autoimmunity. Further experimentation with our cell-free system and 
additional Cathepsins is required to discern the full extent of this 
hypothesis. By testing other antigens we may be able to find other cause 
and effect examples of alternate processing of antigens in different 














Table 1. Peptides used to determine the selectivity of DO for peptide 
binding among immunodominant epitopes. 
List of peptides used in our experiment to test the ability of DO to 
enhance selection of specific peptides out of a given set. Angiotensin I 
peptide did not participate in the experiment and was added to the 
































Figure 1. MALDI-LTQ spectrum of peptides eluted from DR1 
following the incubation with a set of immunodominant peptides. 
Peptides listed in Table 1, with exception of Angiotensin I, were 
incubated with DR1 for 3 hours at 37°C with either DR1 alone, DR1 and 
DM, DR1 and DO, DR1 and DM and DO. DR1 with bound peptides was 
purified through immunoprecipitation by L243 Antibody resin. Peptides 
were eluted by exposing DR1 to 1% TFA. Eluted peptides were separated 
from empty DR1 by filtration through a 10 kDa size exclusion spin filter, 
dried and reconstituted in 50% methanol with 250 fmol of Angiotensin I 
peptide. The peptide samples were analyzed by MALDI-LTQ mass 
spectroscopy at the mass range displaying the peaks of all the peptides 
















Figure 2. MALDI-LTQ spectrum of peptides eluted from DR1 
following the processing of H5N1-HA1 protein. 
Full length H5N1-HA1 protein was incubated with DR1 for 3 hours at 
37°C with either DR1 alone, DR1 and DM, DR1 and DO, DR1 and DM 
and DO. A control incubation of DR1 with DM and DO and no protein 
was also performed for a sample to serve as a background control for the 
experiment. DR1 with bound peptides was purified through 
immunoprecipitation by L243 Antibody resin. Peptides were eluted by 
exposing DR1 to 1% TFA. Eluted peptides were separated from empty 
DR1 by filtration through a 10 kDa size exclusion spin filter, dried and 
reconstituted in 50% methanol with 250 fmol of Angiotensin I peptide. 
Each identified peak was compared to the spectrum of the background 
sample. If an identified peak was present in the background it was 















Figure 3. Mass Spec sequencing of peptides eluted from DR1 
following the processing of H5N1-HA1 protein and relative 
quantitation. 
Full length H5N1-HA1 protein was processed in our cell-free system by 
Cathepsins – B,H and S in 4 different samples containing DR1 and 
combinations of DM and DO: DR1 alone, DR1 + DM, DR1 + DO, DR1 + 
DM + DO. A control sample was processed without the addition of any 
H5N1-HA1 protein but with DR1, DM and DO, to serve as background 
control. Peptides present in each sample were sequenced by Mass 
spectrometry and the relative abundance of each was quantitated by 
peptide correlation profiling/ion intensities in Dr. Leonard Foster’s lab.  
 
(A)  Peptides sequenced from the DR1 alone sample and their relative 
quantities. 
 
(B) Peptides sequenced from the DR1 + DM sample and their relative 
quantities. 
 
(C) Peptides sequenced from the DR1 + DO sample and their relative 
quantities. 
 




(E) Sequence of the full length H5N1-HA1 protein and the location of the 
identified peptides within it. Each core sequence of peptides was color 
coded: Yellow – identified in DR1 alone sample; Green – identified in DR1 
+ DM sample; Turquoise – identified in DR1 + DO sample; Red – 





















A DR1 alone + H5N1-HA1 + CatB + CatH + CatS:  
Peptides:           Relative abundance: 
259 - SNGNFIAPEYAYKIVK - 274 (immunodominant)  3.36
 264 - IAPEYAYKIVK - 274 (immunodominant)  0.72 
208 - QNPTTYISVGTSTLNQRLVPR - 228                 1.46 
247 - TILKPNDAINFE - 258                       0.93 
107 - YPGDFNDYEELKH – 119      0.47 
 
B   DR1+ DM + H5N1-HA1 + CatB + CatH + CatS:  
Peptides:       Relative abundance: 
259 - SNGNFIAPEYAYKIVK - 274 (immunodominant)    490.61 
 259 - SNGNFIAPEYAYKI – 272 (immunodominant)           4.25 
258 - ESNGNFIAPEYAYKIVK – 274 (immunodominant)        11.22 
259 - SNGNFIAPEYAYKIVKKGDS – 278 (immunodominant)      0.96 
260 - NGNFIAPEYAYKIVK – 274 (immunodominant)   2.33      
261 - GNFIAPEYAYKIVK – 274 (immunodominant)   1.45 
262 - NFIAPEYAYKIVK - 274 (immunodominant)   0.61 
84 - DEFINVPEWSYIVEKANPVN – 103                 1.19 
89 - VPEWSYIVEKANPVN – 103      1.92                                                                        
208 - QNPTTYISVGTSTLNQRLVPR – 228                     15.30 
209 - NPTTYISVGTSTLNQRLVPR – 228     1.53 
244 - FFWTILKPNDAIN – 256      4.42 
244 - FFWTILKPNDAINFE – 258      8.54 
245 - FWTILKPNDAIN – 256       7.62 
245 - FWTILKPNDAINFE - 258      7.91 
246 - WTILKPNDAIN - 256       2.78 
246 - WTILKPNDAINFE – 258         15.97 
247 - TILKPNDAINFE – 258       0.63 
 
C   DR1+ DO + H5N1-HA1 + CatB + CatH + CatS: 
Peptides:       Relative abundance: 
259 - SNGNFIAPEYAYKI – 272 (immunodominant)            3.12 
259 - SNGNFIAPEYAYK – 271 (immunodominant)       0.59 
324 - SNRLVLATGLRNSPQ – 338                          2.72  
59 - DLDGVKPLILR – 69                                  0.60 
84 - DEFINVPEWSYIVEK - 98                              0.88 
208 - QNPTTYISVGTSTLNQRLVPR – 228                     11.80 
209 - NPTTYISVGTSTLNQRLVPR – 228     1.58 
246 - WTILKPNDAINFE – 258                              0.54 
247 - TILKPNDAINFE – 258       4.81 




D   DR1+ DO + DM + H5N1-HA1 + CatB + CatH + CatS:  
Peptides:      Relative abundance:     
259 - SNGNFIAPEYAYKIVK - 274 (immunodominant)    312.31 
259 - SNGNFIAPEYAYKI – 272  (immunodominant)          2.63 
258 - ESNGNFIAPEYAYKIVK – 274 (immunodominant)      6.46      
260 - NGNFIAPEYAYKIVK – 274 (immunodominant)       1.96  
324 - SNRLVLATGLRNSPQ – 338              0.83 
84 - DEFINVPEWSYIVEKANPVN – 103         2.24 
208 - QNPTTYISVGTSTLNQRLVPR – 228                     19.95 
209 - NPTTYISVGTSTLNQRLVPR – 228     3.60 
244 - FFWTILKPNDAIN – 256                              1.07 
244 - FFWTILKPNDAINFE – 258                            3.04 
245 - FWTILKPNDAIN – 256       2.96 
245 - FWTILKPNDAINFE - 258      2.82 
246 - WTILKPNDAIN - 256       3.98 
246 - WTILKPNDAINFE – 258      9.93 












DR1 alone - ___ Underlined - immunodominant epitope 
DR1 + DM - ___ 
DR1 + DO - ___ 






Figure 4. MALDI-LTQ spectrum of peptides eluted from DR1 
following the processing of CII protein. 
Full length CII protein was incubated with DR1 for 3 hours at 37°C with 
either DR1 alone, DR1 and DM, DR1 and DO, DR1 and DM and DO. A 
control incubation of DR1 with DM and DO and no protein was also 
performed for a sample to serve as a background control for the 
experiment. DR1 with bound peptides was purified through 
immunoprecipitation by L243 Antibody resin. Peptides were eluted by 
exposing DR1 to 1% TFA. Eluted peptides were separated from empty 
DR1 by filtration through a 10 kDa size exclusion spin filter, dried and 
reconstituted in 50% methanol with 250 fmol of Angiotensin I peptide. 
Each identified peak was compared to the spectrum of the background 
sample. If an identified peak was present in the background it was 















Figure 5. Mass Spec sequencing of peptides eluted from DR1 
following the processing of CII protein and relative quantitation. 
Full length CII protein was processed in our cell-free system by 
Cathepsins – B,H and S in 4 different samples containing DR1 and 
combinations of DM and DO: DR1 alone, DR1 + DM, DR1 + DO, DR1 + 
DM + DO. A control sample was processed without the addition of any 
CII protein but with DR1, DM and DO, to serve as background control. 
Peptides present in each sample were sequenced by Mass spectrometry 
and the relative abundance of each was quantitated by peptide 
correlation profiling/ion intensities in Dr. Leonard Foster’s lab.  
 
(A)  Peptides sequenced from the DR1 alone sample and their relative 
quantities. 
 
(B) Peptides sequenced from the DR1 + DM sample and their relative 
quantities. 
 
(C) Peptides sequenced from the DR1 + DO sample and their relative 
quantities. 
 




(E) Sequence of the full length CII protein and the location of the 
identified peptides within it. Each core sequence of peptides was color 
coded: Yellow – identified in DR1 alone sample; Green – identified in DR1 
+ DM sample; Turquoise – identified in DR1 + DO sample; Red – 





















A   DR1 alone + bCII + CatB + CatH + CatS: 
Peptides:       Relative abundance: 
321 - GPRGEPGTPGSPGPAGAAGN – 340                     0.71 
679 - LQGMPGERGAAG – 690       8.82 
1066 - FTGLQGLPGPPGPSG – 1080                          0.28 
 
 
B   DR1 + DM + bCII + CatB + CatH + CatS: 
Peptides:       Relative abundance: 
388 - EPGIAGFKGEQGPKGEPGPAGPQG – 411(immunodominant)  4.64 
391 - IAGFKGEQGPKGEPGPAGPQG – 411 (immunodominant)  6.54 
396 - GEQGPKGEPGPAGPQG – 411 (immunodominant)   0.20     
1062 - GHRGFTGLQGLPGPP – 1076                        2.24 
1062 - GHRGFTGLQGLPGPPGPSG – 1080                 5.27 
1066 - FTGLQGLPGPPGPSG – 1080      1.92 
 
 
C   DR1 + DO + bCII + CatB + CatH + CatS: 
Peptides:       Relative abundance: 
388 - EPGIAGFKGEQGPKGEPGPAGPQG – 411 (immunodominant)  0.20 
321 - GPRGEPGTPGSPGPAGAAGN - 340     0.12 
595 - FQGLPGPPGPPG – 606                    0.04     
 
 
D   DR1 + DM + DO + bCII + CatB + CatH + CatS: 
Peptides:       Relative abundance: 
391 - IAGFKGEQGPKGEPGPAGPQG – 411 (immunodominant)     0.15 
396 - GEQGPKGEPGPAGPQG – 411(immunodominant)   0.08 
595 - FQGLPGPPGPPG – 606                           0.08    
679 - LQGMPGERGAAG – 690                          0.47 
1062 - GHRGFTGLQGLPGPP – 1076                      1.10 
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DR1 alone - ___ Underlined – Immunodominant epitope 
DR1 + DM - ___     
DR1 + DO - ___ 








Figure 6. Mass Spec sequencing of peptides eluted from DR1 
following the processing of CII protein in the presence of Cathepsin 
V and relative quantitation. 
Full length CII protein was processed in our cell-free system by 
Cathepsins – B,H and V in 4 different samples containing DR1 and 
combinations of DM and DO: DR1 alone, DR1 + DM, DR1 + DO, DR1 + 
DM + DO. A control sample was processed without the addition of any 
CII protein but with DR1, DM and DO, to serve as background control. 
Peptides present in each sample were sequenced by Mass spectrometry 
and the relative abundance of each was quantitated by peptide 
correlation profiling/ion intensities in Dr. Leonard Foster’s lab.  
 
(A)  Peptides sequenced from the DR1 alone sample and their relative 
quantities. 
 
(B) Peptides sequenced from the DR1 + DM sample and their relative 
quantities. 
 
(C) Peptides sequenced from the DR1 + DO sample and their relative 
quantities. 
 




(E) Sequence of the full length CII protein and the location of the 
identified peptides within it. Each core sequence of peptides was color 
coded: Yellow – identified in DR1 alone sample; Green – identified in DR1 
+ DM sample; Turquoise – identified in DR1 + DO sample; Red – 





















A   DR1 alone + bCII + CatB + CatH + CatV: 
Peptides:       Relative abundance: 
679 - LQGMPGERGAAG - 690               5.44 





B DR1 alone + DM + bCII + CatB + CatH + CatV: 
 
Peptides:           Relative abundance: 
679 - LQGMPGERGAAG - 690                       3.08 
913 - IVGLPGQRGERG - 924       7.02 





C   DR1 alone + DO + bCII + CatB + CatH + CatV: 
Peptides:           Relative abundance: 
679 - LQGMPGERGAAG - 690       3.83 
913 - IVGLPGQRGERG – 924                               0.63 





D   DR1 alone + DM + DO + bCII + CatB + CatH + CatV: 
Peptides:           Relative abundance: 
595 - FQGLPGPPGPPG - 606       0.07 
679 - LQGMPGERGAAG - 690       0.99 































DR1 alone - ___ Underlined – Immunodominant epitope 
DR1 + DM - ___     
DR1 + DO - ___ 
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Our experiments have generated a great number of critical observations 
concerning the effects of the DO molecule on antigen presentation by 
MHC class II DR1. This allows us to present a unifying hypothesis for the 
role of DM and DO in antigen presentation.  
 
In the scope of our biochemical experiments we have observed that DO 
can have both enhancing and diminishing effects on the binding of 
peptides. Observations of this sort have been reported before with little or 
no follow-up. At the same time, our studies were able to establish a 
reliable link between the half-time of a peptide’s dissociation, its 
sensitivity to the effects of DM and the effect DO would have on it. As 
noted in Chapter 2, both the quality and the magnitude of the effect of 
DO was related to the half time of dissociation of the protein, much as it 
is in the case of the well studied DM accessory molecule. Unlike 
previously suggested, we have shown that the mechanism of DO is not 
related to that of DM and that DO is able to interact with DR1 on its 
own. This became evident when we demonstrated that DO can have both 
enhancing and diminishing effects on DR1 molecules pre-loaded with a 
short-lived peptide. The separate nature of the mechanisms of DO and 
DM is something that manifests itself in most of our experiments 
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described in Chapters 2 and 3. While a significant finding on its own, we 
were able to expand our studies and determine the exact mode of 
interaction between DO and DR1. By experimenting with a mutant DR1 
molecule that was stabilized in a receptive conformation we found that 
DO could still affect its binding of peptides. Since the mutant DR1 
molecule could not adopt the closed conformation, this means that the 
mechanism of the effect of DO does not involve forcing the DR1 
molecules to become receptive. At the same time, dissociation 
experiments in Chapter 2 have shown that DO has little to no effect on 
the dissociation of peptides. We hypothesized that this was because DO 
could not interact with a closed or compact conformation of the DR1 
molecule. Our hypothesis was proven correct with our SPR binding 
experiments depicted in Chapter 3 which showed that DO can only 
interact with receptive DR1 molecules but not the closed compact 
conformers. 
 
To explain our observations we purpose a unifying theory of the 
mechanism of DM and DO in Class II antigen presentation. We theorize 
that DO requires DM to generate the peptide-receptive conformation in 
DR1 molecules, while at the same time imposing its level of selection on 
the antigenic peptides processed by the Class II system. When the DR1 
molecules become receptive, DO is able to exert its effect and enhance 
the presentation of some peptides (most likely long-lived) while 
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diminishing the presentation of other peptides (most likely short-lived). 
This way DO would impose another level of selection on the antigenic 
peptide processing in addition to that of DM. The presence of DO most 
likely results in a narrower peptide repertoire than that generated by DM 
alone.  
 
As a validation of our theory behind the effect of DO and DM, our full 
length antigen processing experiments described in Chapter 4 have 
shown that the nature of the peptides bound to DR1 is different in the 
presence of DO, DM and DO with DM together. By utilizing our cell-free 
processing system we have discovered that certain antigens present their 
immunodominant peptides better in the presence of DM with DO having 
little or no effect on the amount of peptide presented. At the same time 
we found that the presence of DO could significantly alter the 
presentation of the immunodominant peptide derived from type II 
collagen processing, to the point where it is barely detectable. This opens 
up a whole new research approach in studying Class II antigen 
presentation. By thoroughly experimenting with the processing of 
antigenic proteins we will be able to find more examples of accessory 
molecules playing a significant role in antigen presentation and perhaps 
even disease pathology. This, in turn, opens up new possibilities to apply 
treatment through affecting the MHC class II accessory molecules 
through chemical and biological means. In addition, we have provided 
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evidence for how the variable processing of antigens in different 
immunological compartments that contain different class II digestive 
enzymes may lead to autoimmunity. While more research has to be done 
to follow up on our discoveries, it is evident that experiments with our 
cell-free system have to expanded to accommodate the fact that DO as 






















Discovering the altered receptive conformation in DR1 molecules 
through circular dichroism 
DO binds to a receptive conformation of DR1. We theorized that upon 
binding DO would force a receptive DR1 molecule to adopt a theoretical 
“super-receptive” conformation. This conformation would have a peptide 
groove more open than that in a peptide-receptive DR1, which would 
make the DR1 molecule less stable. If this is the case then the thermal 
stability of DR1 would be diminished even further in the presence of DO. 
To test this we measured the circular dichroism (CD) of DR1 alone, DO 
alone and DR1 together with DO. The concentrations had to be adjusted 
to make sure that the signal generated by DO would not overtake the 
signal generated by DR1 (Fig. 1). 
 
Additionally the same experiment was repeated with a receptive DR1 
molecule. DR1 was preloaded with Y308A peptide for 3 days and excess 
peptide was removed before the start of the experiment, while the 
samples were kept on ice. The CD of DR1-HA(Y308A) alone, DO alone 
and DR1-HA(Y308A) together with 5 μM DO was determined using the 
same parameters as before (Fig. 2). In each case the temperature 
changes of the transition points were minor and DO seemed to have 




Figure 1. Circular dichroism melting curve scan of DR1 in the 
presence of DO  
(A)  CD scan of 10 μM DR1 alone, 10 μM DO alone and 20 μM DR1 
together with 5 μM DO over a temperature range of 25 °C to 100 °C, with 
an increase rate of 1 °C/min.  
(B)  Derivative of the CD scan, top of each peak represents the melting 









Figure 2. Circular dichroism melting curve scan of DR1-HA(Y308A) 
in the presence of DO  
(A)  CD scan of 20 μM DR1 alone, 5μM DO alone and 20 μM DR1 together 
with 5 μM DO over a temperature range of 25 °C to 100 °C, with an 
increase rate of 1 °C/min.  
(B)  Derivative of the CD scan, top of each peak represents the melting 
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